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Outline of the thesis 
In 2000 obesity was declared a chronic disease by the World Health 
Organization emphasizing the importance of the obesity epidemic in the 21st 
century. According to figures from 2005 of the adult population in the 
Netherlands provided by the Central Bureau of Statistics 44.9% was 
overweight (Body Mass Index (BMI) >25kg/m2), while obesity has a prevalence 
of 10.8% (BMI between 30-40 kg/m2). Because clear data of the prevalence of 
morbid obesity (BMI above 40 kg/m2) in the Netherlands are lacking, these 
results were extrapolated using the outcome of similar North American studies. 
The prevalence of morbid obesity in the Netherlands was estimated to be 1.5% 
of the adult population. In Figure 1.1 the data of 2005 for the Netherlands are 
summarized. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Weight class prevalence in the Netherlands in 2005; in total 44.9% of the adult 
population is considered overweight. Adapted from Centraal Bureau voor de Statistiek, 
Voorburg/Heerlen. 
 
Several diseases with high prevalence in the population are associated with 
obesity. Cardiovascular diseases and type II diabetes mellitus comprise the 
majority of co-morbidities related to obesity. It is reported that obese patients 
are at a 5-20 times greater risk for developing type II diabetes mellitus. 
Cardiovascular diseases are directly correlated to type II diabetes mellitus and 
it is therefore not surprising that obesity results in a 4-6 fold increased risk for 
cardiovascular diseases. In addition, a 40 fold increased risk of dying from 
sudden cardiac arrest is reported. Besides type II diabetes mellitus and 
cardiovascular diseases cancer is also a serious condition associated with 
obesity. A 4-6 fold increased risk for breast and colon cancer is reported in 
obesity. These figures illustrate that the morbidities of obesity have a major 
impact on Dutch healthcare, reflected by an estimated €505 million direct costs 
and €2 billion indirect costs annually1,2. 
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12⏐Chapter 1 
Losing weight is the most effective treatment of, or prophylaxis for the co-
morbidities accompanying obesity. In general two approaches are available: 
non-invasive (diet, physical training, psychotherapy and pharmacotherapy) and 
invasive (bariatric surgery = surgical treatment of morbid obesity) interventions. 
Non-invasive therapy leads to reduced body weight with a maximum of 
approximately 10% and is therefore not suitable for the morbidly obese 
population. On the other hand, invasive therapy (bariatric surgery) can result in 
weight loss in the order of 50-70% of excess weight3-5. In addition, bariatric 
surgery is able to dramatically reduce the risk for co-morbidities, like type II 
diabetes and cardiovascular diseases6-8. Therefore bariatric surgery is 
considered the most effective treatment of morbid obesity.  
The types of surgery which are covered by this thesis will shortly be discussed. 
Bariatric surgery is based on two main principles: malabsorption and restriction. 
The ingested food is either not properly absorbed by the gut or intake is limited. 
In malabsorptive surgery, a short bowel is created, while in restrictive surgery 
the stomach size is reduced9,10. The result is substantial weight loss, which 
averages 40 kg (14.2 BMI points) reported by Buchwald et. al. in a meta-
analysis of all types of surgical procedures11.  
Recently laparoscopic surgery has gained popularity because of its less 
invasive nature12. Morbidly obese patients are at risk of developing serious 
postoperative complications13. Laparoscopic surgery is thought to decrease the 
postoperative complication rate dramatically. Laparoscopic gastric banding 
compared to an ‘open’ restrictive procedure, like vertical gastric banding 
showed reduced direct postoperative complications14. 
Vertical banded gastroplasty 
This procedure was initially described by Mason and has probably been the 
technique that has popularized bariatric surgery due to its simplicity and 
relative safety15. In short a small pouch of the stomach (approximately 
15-20 ml) is created with a linear stapler precisely to the angle of His and a 
Dacron band placed through the window formed by a circular stapler leaving a 
very small opening for food to pass from the small pouch to the remaining 
stomach. Because of the small capacity of the gastric pouch the amount of 
ingested food is considerably limited leading to extensive weight loss16. Due to 
the relatively large numbers of long term failure this procedure is not performed 
routinely anymore.  
Adjustable laparoscopic gastric banding 
The adjustable gastric band is made of soft silicone and equipped with an 
elastic balloon that can be inflated to the desired volume by means of injection 
postoperatively. After inflation the outlet diameter will be reduced leading to 
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diminished food intake and consequently to weight loss. Belachew developed 
in the early nineties a laparoscopic technique17. In short, the adjustable gastric 
band is placed laparoscopically around the stomach. On indications, for 
definitive positioning of the band, a 15-ml calibration balloon advanced by the 
anesthetist and pulled up to the gastroesophageal junction is placed right 
below the cardia. Under this balloon the band is closed and with three or four 
sutures the ventral aspect of the greater curvature of the stomach is fixed to the 
pouch to ensure a stable anterior position of the band. Finally the band is 
placed in the perigastric fascia. Nowadays all surgeons use the pars flaccida 
technique in which the mesentery of the proximal stomach is included in the 
band. Six weeks postoperatively the band is insufflated when weight loss is 
insufficient (less than 6 kg). The band is insufflated as often as needed to 
induce sufficient weight loss (approximately 0.5-1 kg weight loss per week). 
Gastric bypass  
This technique was introduced by Mason18 and has been adjusted to the 
technique currently carried out19. Although gastric bypass surgery is a 
combination of malabsorptive and restrictive surgery, its effects on weight loss 
are thought to arise from the restrictive component of the surgical intervention. 
In short a vertical gastric pouch is created. To create the Roux limb the jejunum 
is transected at approximately 30 cm from the ligament of Treitz where a 
comfortable length of mesentery exists. The Roux limb is measured 
75 - 150 cm distally and an end-to-side anastomosis is created with the 
proximal jejunal limb. The gastrojejunostomy is created using either a circular 
stapled end-to-end anastomosis, a linear stapler technique or a hand sewn 
technique.  
Biliopancreatic diversion  
This malabsorptive surgical technique was introduced by Scopinaro20. It 
consists of a distal gastrectomy with a long Roux-en-Y reconstruction. The 
enteroenterostomy is placed 200 cm distal to the gastroenterostomy and 50 cm 
proximal to the ileocaecal valve. This results in three intestinal limbs, the 
alimentary loop from the gastroenterostomy to enteroenterostomy, the common 
loop from the enteroenterostomy to the ileocaecal valve and the pancreatico-
biliary loop from the duodenum to the enteroenterostomy. The role of the 
gastrectomy is to allow a rapid emptying of gastric content into the ileum. The 
effect of the operation is the creation of a “controlled” short bowel. 
 
The effect of bariatric surgery on body weight, type II diabetes and insulin 
resistance is further discussed in Chapter 2. Bariatric surgery leads to 
decreased nutrient intake. Consequently adipose tissue mass decreases which 
14⏐Chapter 1 
results in weight loss. Moreover, it is reported that weight loss is associated 
with decreased accumulation of fat metabolites in organs crucial in glucose 
metabolism (liver and muscle)21,22. In this review hypotheses regarding the 
effect of these changes on insulin sensitivity after bariatric surgery are 
discussed. Furthermore, theories on the effect of changes in gut anatomy due 
to bariatric surgery on gut hormones and their impact on insulin sensitivity are 
evaluated in this chapter. 
 
The experimental part of this thesis addresses two topics in bariatric surgery. 
The first topic relates to plasma levels of satiety hormones after bariatric 
surgery and the second topic regards the low-grade inflammatory condition 
associated with morbid obesity and the effect of bariatric surgery on this 
condition. 
In Chapter 3 plasma levels of satiety hormones after bariatric surgery are 
studied. As mentioned before, operative techniques in bariatric surgery can be 
divided in malabsorptive (biliopancreatic diversion) and restrictive (gastric 
bypass, vertical gastric banding and gastric banding) procedures. The 
mechanism behind weight loss in procedures which are solely based on 
restriction is well defined. Due to a smaller stomach size already small amounts 
of food results in distention of the gastric pouch inducing rapid satiety and 
prohibiting further food intake. Interestingly, compared to solely restrictive 
procedures, despite an equal size of the gastric pouch, gastric bypass surgery 
was reported to result in improved weight loss11,23. The influence of gastric 
bypass on postoperative plasma levels of satiety hormones could partly 
account for this finding. In contrast to vertical banded gastroplasty (VBG) and 
gastric banding gastric bypass surgery results in bypassing of the fundus of the 
stomach. Cells of the fundus play a role in regulating food intake: in absence of 
food in the fundus the cells produce the orexigenic hormone ghrelin24. 
Paradoxically literature data show that gastric bypass surgery results in 
decreased or unaltered plasma levels of ghrelin which consequently reduced 
appetite leading to decreased food intake and weight loss25-27. In this context 
the effect of VBG and gastric banding on plasma ghrelin levels and other 
satiety hormones leptin and insulin were studied. The data are presented in the 
background of reported data on gastric bypass surgery.  
 
Circulating levels of the satiety hormone leptin were also studied in an 
immunological perspective. Bariatric surgery results in a rapid decrease in food 
intake which starts with a short period of fasting followed by a continuous 
reduced food intake. During fasting plasma leptin levels are reported to 
decrease rapidly28. Recently immunoregulatory properties of leptin are reported 
which are reviewed in more detail in Chapter 4. The immunoregulatory function 
of leptin was largely deduced from literature data showing immunological 
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abnormalities in leptin deficient animals29,30. In line the general view is that low 
plasma leptin levels are unfavorable for an individual. In this context we have 
investigated circulating leptin levels during the first days after bariatric surgery 
when the patient is in a fasting condition. 
 
The second topic addressed in this thesis concerns the low-grade inflammatory 
condition associated with morbid obesity and the effects of bariatric surgery on 
this condition. The aim of bariatric surgery is to reduce weight as well as the 
prevalence of co-morbidities associated with morbid obesity. Considerable 
evidence from human studies indicates a role of inflammation as a causal 
factor in obesity induced morbidities31,32. It is well known that in man obesity is 
associated with increased levels of inflammatory cytokines like Tumor Necrosis 
Factor alpha (TNF-α), Interleukin-6 (IL-6) and Interleukin-8 (IL-8)33-35. In 
addition obesity is associated with increased circulating levels of acute phase 
proteins36-40. Supplementary evidence for the involvement of inflammation in 
co-morbidities associated with morbid obesity has been obtained by studying 
the effect of aspirin treatment of obese patients. The aspirin treatment induced 
a decrease in inflammatory markers, which was accompanied by an increase in 
insulin sensitivity an important co-morbidity of obesity41. Bariatric surgery not 
only leads to weight loss, but also results in reduction of the low-grade 
inflammatory condition39,42,43. 
 
The low-grade inflammatory condition is further characterized in Chapter 5 by 
studying endothelial cell activation. Earlier studies show that morbid obesity is 
associated with increased plasma levels of cytokines and acute phase 
proteins39. Moreover, circulating monocytes of obese individuals express more 
Nuclear Factor-kappa B (NF-κB) than monocytes derived from normal weight 
healthy controls44. Furthermore, morbid obesity is also associated with 
activation of the complement system42. These observations show that different 
aspects of the innate immune response are activated in morbidly obese 
individuals. Endothelial cell activation is one of the initial steps in inflammatory 
processes. It is associated with several diseases which are also related to 
morbid obesity45. In this perspective it was hypothesized that morbid obesity is 
associated with increased endothelial cell activation. Bariatric surgery results in 
decreased incidence of co-morbidities of morbid obesity11. Consequently 
endothelial cell activation could decrease after bariatric surgery. Therefore 
plasma levels of endothelial cell activation markers were studied preoperatively 
as well as during the first two years after bariatric surgery. Moreover, pre- and 
postoperative plasma levels of resistin and adiponectin, which are reported to 
be mediators of endothelial cell activation, were measured.  
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In Chapter 6, neutrophil activation in morbidly obese individuals was evaluated. 
Neutrophils represent one of the most prominent components of the innate 
immune system displaying strong phagocytic and anti-microbial activity. 
Moreover, neutrophils play an important role in the pathophysiology of non 
alcoholic steatohepatitis (NASH), a condition frequently associated with morbid 
obesity46. Therefore it was hypothesized that neutrophils are activated in 
morbidly obese patients. Circulating levels of neutrophil activation makers as 
well as membrane bound expression of neutrophil activation markers are 
studied in morbidly obese patients. Moreover, the long term effect of bariatric 
surgery on plasma levels of neutrophil activation markers is studied.  
 
In the context of Chapter 5 it was shown that, despite substantial weight loss, 
several parameters of the low-grade inflammatory condition associated with 
morbid obesity did not decrease during the first months after bariatric surgery39. 
Interestingly, the low-grade inflammatory condition is thought to play a major 
role in the pathophysiology of insulin resistance47. Therefore, insulin resistance 
as well as circulating inflammatory mediators were measured in subjects that 
had lost 26% excess weight approximately three months after restrictive 
bariatric surgery (Chapter 7). Several authors have stated that insulin 
resistance depicted as HOMA-IR levels is improving directly after restrictive 
bariatric surgery48-50. A second goal of this study was to compare both HOMA-
IR and Steady State Plasma Glucose (SSPG) levels as measurements of 
insulin resistance in the early postoperative period.  
 
Insulin sensitivity increases in the long term after bariatric surgery51. In Chapter 
2 it is suggested that a decrease in macronutrient intake could partly be 
responsible for this effect of bariatric surgery on insulin resistance. In Chapter 8 
the opposite, the effect of overfeeding on insulin sensitivity, is studied. The 
starting point was the reported data on overfeeding of rats resulting in 
decreased insulin sensitivity52. Interestingly, this has not been shown in a 
human study53. This could be explained by the selection of healthy normal 
weight individuals for these experiments. Therefore, the effect of overfeeding 
was studied in individuals with a history of morbid obesity, insulin resistance 
and low-grade inflammation. These individuals might be genetically 
predisposed to develop insulin resistance and a low-grade inflammatory 
condition in response to morbid obesity. The study was designed to investigate 
in weight stable individuals approximately three years after bariatric surgery the 
effect of overfeeding for seven days on insulin sensitivity and inflammatory 
markers.  
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Abstract 
Morbid obesity is associated with serious co-morbidities like cardiovascular disease, insulin 
resistance and type 2 diabetes (T2DM). Conventional therapy for T2DM consists of weight loss and 
pharmacotherapy. Recently, surgery was suggested to be the best treatment for T2DM in morbid 
obese patients. This review will focus on the effects of bariatric surgery on T2DM. The outcomes of 
different bariatric techniques will be discussed. Moreover, the question why weight loss is 
advantageous in treating T2DM will be addressed. In this view the effect of decreased nutrient 
intake, decreased intracellular fatty acid accumulation as well as decreased body fat mass on 
T2DM are discussed. 
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Introduction 
“Who would have thought it? An operation proves to be the most effective 
therapy for adult-onset diabetes mellitus”. It was this paper from Walter Pories, 
which was the first to demonstrate the effectiveness of bariatric surgery on type 
2 diabetes mellitus (T2DM)1.  
T2DM is a growing problem in modern society. In 2002 the prevalence of 
T2DM in the United States was 6.3%. 1.3 million inhabitants developed T2DM 
annually, an epidemic that was assessed to cost 132 billion dollars per year2. 
Treatment of T2DM is aimed at normalizing blood glucose levels by improving 
insulin sensitivity and/or increasing insulin secretion. Besides pharmacological 
interventions weight loss is very effective in T2DM patients3,4. Although diet 
induced weight loss can be favorable in obese individuals, not al obese 
patients can benefit from this treatment. In a subcategory of obesity, the 
morbidly obese patient (Body Mass Index (BMI)>40 kg/m2), this intervention is 
considered inefficient5-7. Within the morbidly obese population approximately 
15% suffer from T2DM8. Conventional therapy is able to reduce weight with a 
maximum of 10%. This only is achieved when psychotherapy, physiotherapy 
and dieting are combined9. Most of the patients are not capable of sustaining 
weight loss for more than five years. Moreover, 10% weight loss in morbid 
obese individuals is negligible compared to their substantial overweight. 
Currently, the most effective way to lose weight is bariatric surgery. As was 
reported by Buchwald surgically treated patients lose weight with a mean of 
40 kg (14.2 BMI points) with excellent long term results8. Moreover, bariatric 
surgery appears cost effective within three years after surgery. In an 
observational two cohort study, 1035 subjects receiving bariatric surgery were 
compared with 5746 control subjects. Over a five year period the total costs per 
1000 patients were 19.5 and 25.2 million Canadian dollars for the bariatric and 
control group respectively10.  
This review focuses on the effect of bariatric surgery on T2DM. Both clinical 
and biochemical evidence will be discussed. Firstly we describe evidence in 
literature that bariatric surgery is an effective treatment of T2DM in morbid 
obese subjects. Next we focus on the types of surgery frequently used and the 
difference in effect of these surgical techniques on resolution of T2DM. The last 
part of this review addresses the question why weight loss is effective in 
treating T2DM.  
Bariatric surgery as a possible treatment of T2DM in morbidly 
obese patients 
Bariatric surgery is a subspecialty of surgery dealing with the surgical treatment 
of obesity. Numerous studies have been performed showing effectiveness of 
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this intervention in morbidly obese individuals11-13. Since the original article of 
Pories was published another 30 studies have demonstrated similar effects of 
bariatric surgery on T2DM. Pories included 608 patients with a follow-up of 
14 years after gastric bypass surgery. Impaired glucose intolerance recovered 
in 150 of 152 patients. Of the 146 patients with T2DM 83% (121 patients) were 
cured. In another study 64% resolution of T2DM one year after gastric banding 
was reported in a group of 50 patients; 26% showed improved glucose control 
and 10% did not improve14. Most of these studies are summarized in the meta-
analysis by Buchwald8. In this meta-analysis evidence of the effect of bariatric 
surgery on the different co-morbidities accompanying morbid obesity is 
described. In total 136 primary studies (19,388 patients) were included 
(5 randomized controlled trials, 28 nonrandomized controlled trials and 101 
uncontrolled case series). Resolution of diabetes was defined as 
discontinuance of all diabetes-related medications as well as the ability to 
maintain blood glucose levels within the normal range. Studies reporting on 
diabetes showed 76.8% resolution (1417 out of 1846 patients). If studies 
reported both resolution and improvement, or only improvement of diabetes, 
85.4% (414 out of 485 patients) experienced resolution or improvement of 
diabetes. Overall, plasma glucose levels in diabetic patients decreased with an 
average of 3.97 mmol/l (296 patients). Matching data were found in studies 
published after the inclusion date of the meta-analysis. Recently, between 83% 
and 88% resolution of T2DM was reported15-19. However, other studies report 
lower resolution rates20,21. The Swedish Obese Subjects (SOS) study reports 
72% resolution within the first two years following surgery22. After ten years 
36% of the patients with preoperative diabetes were cured. The SOS study is a 
non-randomized trial comparing 2010 patients who received bariatric surgery 
with 2037 conventional treated individuals. After ten years 13% of the patients 
with overt T2DM at the start of the study were cured in the conventional treated 
group. Moreover, the incidence of T2DM in the surgical group was 1% and 7% 
after two and ten years respectively. In contrast, in the conventional treated 
group the incidence of T2DM was 8% and 24% after two and ten years. These 
data indicate that, even in the long term follow-up, bariatric surgery is superior 
to conventional therapy in morbid obese patients.  
A possible explanation for the differences observed in resolution of diabetes 
after bariatric surgery can be the history of T2DM before surgery. It was 
reported that the duration of T2DM before bariatric surgery is inversely 
correlated with the restoration of β-cell function postoperatively. With increasing 
duration of T2DM before surgery (>3 years), the probability of β-cell recovery 
decreased14,19,23,24. Moreover, older subjects with T2DM are also reported to 
benefit less from bariatric surgery25. 
In literature evidence exists concerning cost effectiveness of bariatric surgery 
regarding T2DM. In the article of Sampalis on impact of bariatric surgery on 
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health care costs the cumulative endocrinological costs per 1000 patients were 
764,104 and 986,381 Canadian dollars for the bariatric and control group 
respectively10. Moreover, another study comparing the pharmaceutical costs 
between a bariatric and obese control group reported that surgery significantly 
reduced the costs of T2DM26. Furthermore, a 77.3% reduction of costs related 
to T2DM was reported in gastric bypass patients27. These studies show that 
bariatric surgery is a cost- effective treatment for T2DM. 
Although the effect of bariatric surgery on resolution of T2DM is promising 
some reservations have to be made. Many studies were not randomized and 
follow-up was low. The Swedish Obesity Subjects (SOS) study was a well 
matched non-randomized trial comparing surgery with conventional therapy. In 
conclusion, more randomized studies are needed comparing conventional 
therapy with bariatric surgery with respect to resolution of T2DM28. 
Different types of bariatric surgery techniques are available to reduce weight. 
According to the above mentioned meta-analysis, these surgical approaches 
have different outcomes on T2DM8 (Table 2.1.). 
 
Table 2.1  Weight loss and T2DM resolution after bariatric surgery. 
 Gastric bypass Biliopancreatic diversion Gastric banding 
% EWL 62.56% (56.68-66.45)a 70.12% (66.34-73.91)a 47.4% (40.68-54.23)a 
% T2DM resolution 83.7% (77.3-90.1)a 98.9% (96.8-100)a 47.9% (29.1-66.7)a 
a Mean (95% confidence interval), EWL: excess weight loss, T2DM: type II diabetes mellitus. 
 
Types of surgery  
Bariatric surgery is based on two main principles: malabsorption and restriction. 
The ingested food is either not properly absorbed by the gut or intake is limited. 
In malabsorptive surgery a short bowel is created while in restrictive surgery 
the stomach is reduced12,13. The result is substantial weight loss which 
averages 40 kg (14.2 BMI points)8. We will discuss three major types of 
surgery: gastric bypass (Figure 2.1A), biliopancreatic diversion (Figure 2.1B) 
and adjustable laparoscopic gastric banding (Figure 2.1C). 
Recently laparoscopic surgery has gained popularity because of its less 
invasive nature29. Morbid obese patients are at risk of developing serious 
postoperative complications30. Laparoscopic surgery is thought to decrease the 
postoperative complication rate dramatically. Laparoscopic gastric banding 
compared to an ‘open’ restrictive procedure like vertical gastric banding 
showed reduced direct postoperative complications31.  
In our hospital laparoscopic gastric banding is preferred. In our opinion 
laparoscopic gastric banding is a safe procedure which results in substantial 
weight loss. If weight loss is insufficient a conversion to a gastric bypass is 
performed. Currently morbidly obese individuals with a BMI over 60 kg/m2 are 
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treated with biliopancreatic diversion. The rationale for this approach is not 
entirely evidence based since randomized controlled trials comparing different 
surgical techniques are limited. 
 
 
A                                    B                                          C   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 A. Gastric bypass (source: American Society of Bariatric Surgery) 
 B. Biliopancreatic diversion (source: American Society of Bariatric Surgery) 
 C. Gastric banding (source: American Society of Bariatric Surgery) 
Gastric bypass 
Gastric bypass surgery is a combination of malabsorptive and restrictive 
surgery (Figure 2.1A). This technique was introduced by Mason32 and has 
been adjusted to the technique currently carried out33. In short a vertical gastric 
pouch is created. To create the Roux limb, the jejunum is transected at 
approximately 30 cm from the ligament of Treitz where a comfortable length of 
mesentery exists. The Roux limb is measured 75 - 150 cm distally and an end-
to-side anastomosis is created with the proximal jejunal limb. The gastro-
jejunostomy is created using either a circular stapled end-to-end anastomosis, 
a linear stapler technique or a hand sewn technique.  
Biliopancreatic diversion  
This malabsorptive surgical technique was introduced by Scopinaro34. It 
consists of a distal gastrectomy with a long Roux-en-Y reconstruction (Figure 
2.1B). The enteroenterostomy is placed 200 cm distal to the gastroenterostomy 
and 50 cm proximal to the ileocaecal valve. This results in three intestinal 
limbs, the alimentary loop from the gastroenterostomy to enteroenterostomy, 
the common loop from the enteroenterostomy to the ileocaecal valve and the 
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pancreaticobiliary loop from the duodenum to the enteroenterostomy. The role 
of the gastrectomy is to allow a rapid emptying of gastric content into the ileum. 
The effect of the operation is the creation of a “controlled” short bowel. 
Adjustable laparoscopic gastric banding 
The adjustable gastric band is made of soft silicone and equipped with an 
elastic balloon that can be inflated to the desired volume by means of injection 
postoperatively. After inflation the outlet diameter will be reduced, leading to 
diminished food intake and consequently to weight loss. Belachew developed 
in the early nineties a laparoscopic technique34. In short the adjustable gastric 
banding is placed laparoscopically around the stomach. For definitive 
positioning of the band a 15-ml calibration balloon advanced by the anesthetist 
and pulled up to the gastroesophageal junction is placed right below the cardia. 
Under this balloon the band is closed and with three or four sutures the ventral 
aspect of the greater curvature of the stomach is fixed to the pouch to ensure a 
stable anterior position of the band. Six weeks postoperatively the band is 
insufflated when weight loss is insufficient (less than 6 kg). The band is 
insufflated as often as needed, to induce sufficient weight loss (approximately 
0.5-1 kg weight loss per week). 
Comparing different surgical techniques 
A resolution of T2DM of 98.9% of the type 2 diabetic patients is seen after 
biliopancreatic diversion. This number was 83.7% for gastric bypass and 47.9% 
for laparoscopic gastric banding8. The difference was thought to be caused by 
the lack of malabsorption in laparoscopic gastric banding. However, in the 
same meta-analysis, vertical gastric banding, which is a purely restrictive 
procedure, shows a 71.6% resolution of T2DM. Differences in outcome can 
also be explained from inexperience with laparoscopic gastric banding. This 
can result in insufficient weight loss and poor resolution of diabetes. 
Laparoscopic gastric banding has lately been optimized, resulting in less 
complications and better weight loss35.  
Recently, our group found contrasting data on insulin resistance (IR) after 
bariatric surgery. According to literature, bariatric surgery leads to increased 
insulin sensitivity directly after surgery. We found however no change in insulin 
sensitivity during the first months after restrictive bariatric surgery. In another 
group, which was weight stable (approximately two years after surgery), insulin 
sensitivity was improved36. We hypothesize that during the first months after 
surgery the weight losing individuals endures metabolic stress. This is 
illustrated by the observation that inflammatory parameters like C-Reactive 
Protein (CRP) and the endothelial activation markers soluble Intercellular 
Adhesion Molecule-1 (sICAM-1) and soluble Vascular Cell Adhesion 
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Molecule-1 (sVCAM-1) are still increased during the first months after 
surgery37,38. 
Biliopancreatic diversion and gastric bypass have shown remarkable outcomes 
on diabetes. Within a few days after surgery, glucose levels decreased 
substantially. Also insulin sensitivity, measured using clamp studies increased 
rapidly39,40. During this period the amount of excess weight still was 80%. It is 
hypothesized that the effect of this type of surgery on diabetes can not be 
explained from weight loss41. Hormones derived from the gut are thought to 
play an important role in resolution of T2DM directly after surgery41. This aspect 
will be elaborated in the next paragraph. 
Gut hormones explain it all? 
Administration of oral glucose leads to increased plasma insulin levels, much 
more than compared to intravenous administration of glucose. This effect is 
thought to arise from incretins secreted by the foregut and is called the incretin 
effect42,43. It was calculated that the incretin effect is responsible for 50-70% of 
the insulin response to oral glucose44. The two most important incretins are 
Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like 
Peptide 1 (GLP-1). GIP is almost exclusively secreted in the duodenum by 
K-cells upon stimulation with lipids and absorbable carbohydrates45. Meal 
ingestion results in a 10 to 20-fold increase in the plasma concentration46. 
GLP-1 is secreted by L-cells of the intestinal mucosa upon presence of 
nutrients. GIP is more expressed in the proximal intestine, while GLP-1 is 
predominately expressed in the terminal ileum47,48. Experiments neutralizing 
these incretins rendered animals and humans glucose intolerant49, 50. Different 
hypotheses have been postulated on the origin of T2DM resolution taken into 
account the activity of incretins. These hypotheses are based on the finding 
that almost directly after malabsorptive surgery plasma glucose concentrations 
normalized and the need for insulin decreased without substantial weight loss. 
The only difference is that ingested food is bypassed and that the duodenum 
and proximal jejunum do not encounter food any more. Also of importance is 
that the terminal ileum now encounters undigested food more rapidly after 
ingestion. Pories and Rubino have based their hypothesis on the absence of 
food in the proximal gut41,51. Morbid obese patients have increased GIP plasma 
levels before bariatric surgery. It is speculated that GIP plasma levels are 
increased because of GIP resistance induced by an anti-incretin produced by 
the fore-gut. After gastric bypass, exclusion of these cells from the entero-
insulinemic axis can result in decreased anti-incretin levels. Consequently 
plasma levels of GIP decrease52. Until now the anti-incretin has not been 
found. Moreover, this hypothesis does not take into account the effect of 
unprocessed food in the terminal ileum. This, according to another hypothesis 
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leads to increased postprandial GLP-1 production and increased insulin 
production and sensitivity53.  
Purely restrictive surgery does not result in exclusion of the gut from ingested 
food. In contrast to our findings, other studies report increased insulin 
sensitivity directly after restrictive surgery38. These observations point out that 
alterations in plasma gut hormones levels are not solely responsible for the 
curative effect of bariatric surgery on T2DM. Weight loss is also responsible for 
improved insulin sensitivity after bariatric surgery. In the following paragraphs 
we will elaborate on this subject.  
Why weight loss is advantageous  
The low-grade inflammatory condition observed in obese individuals is thought 
to play a key role in the pathophysiology of obesity induced Insulin Resistance 
(IR) and T2DM54,55. Inflammatory mediators like Tumor Necrosis Factor alpha 
(TNF-α) are reported to induce IR55. Moreover, high dose salicylate treatment 
for 14 days of patients with T2DM was reported to improve insulin 
sensitivity56-58. Substantial weight loss reduced the low-grade inflammatory 
condition37. It is tempting to speculate that weight loss, by reducing 
inflammation, is an effective treatment for IR and T2DM. We will focus on the 
different mechanisms described in literature by which weight loss can facilitate 
improved insulin secretion and sensitivity. The following conditions associated 
with weight loss are discussed together with their contribution to increased 
insulin sensitivity and secretion: decreased intake of nutrients, decreased 
intracellular accumulation of fatty acids, and decreased fat mass. 
Decreased intake of nutrients 
Obesity is amongst others caused by a misbalance the metabolic need for and 
the intake of nutrients. Several observations link the excessive intake of 
nutrients directly to decreased insulin sensitivity. Overfeeding rats for one week 
resulted in reduced insulin sensitivity59. Moreover, liposuction in individuals with 
impaired glucose tolerance did not result in increased insulin sensitivity60. 
Recently we performed an overfeeding study in humans, which confirmed the 
data obtained in rat studies36. Studies in which overfeeding induced IR no 
change in BMI was observed, whereas insulin sensitivity decreased. The 
common denominator in the liposuction and overfeeding studies is increased 
nutrient intake. This leads to the hypothesis that increased nutrient intake itself 
can induce IR. Further support for this hypothesis is the observation that 
morbid obese individuals with a stable weight after bariatric surgery, are 
healthier than matched obese with similar BMI who did not loose weight61. 
Patients treated with bariatric surgery have less nutrient intake compared to the 
matched obese individuals. 
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A possible mechanism behind these observations could imply the formation of 
reactive oxygen species (ROS) and their ability to activate the pro-inflammatory 
Nuclear Factor (NF)-κB pathway. In man a single oral dose of 75 gram glucose 
resulted in increased formation of ROS by polymorphonuclear and 
mononuclear cells. Moreover, concurrently the circulating concentration of the 
antioxidant α-tocopherol decreased62. Furthermore, a single dose of lipids 
(33 gram per 100 ml, 300kCal), resulted in increased ROS production by 
leucocytes and increased thiobarbituric acid–reactive substances (TBARS) 
while α-tocopherol plasma levels were not decreased. An isocaloric dose of 
protein only resulted in increased ROS production by leucocytes. It did not 
result in elevated TBARS or decreased α-tocopherol plasma levels63. These 
results led to the hypothesis that nutrient intake can result in increased 
oxidative stress. Fasting decreased ROS formation by leucocytes and 
decreased systemic oxidative stress further supporting the hypothesis that 
increased nutrient intake leads via ROS formation to IR64,65. 
ROS are reported to activate the NF-κB pathway resulting in increased pro-
inflammatory cytokine production66. NF-κB is a heterodimer, generally 
consisting of RelA (p65) and p50 molecules. It resides in the cytosol where it is 
bound to IκB, which inhibits its activity. Upon activation of the cell, for example 
by lipopolysaccharides or TNF-α, IκB becomes phosphorylated by the IκB 
kinase (IKK) complex and detaches from NF- κB. The IKK complex consists of 
IKK-α, IKK-β and a regulatory unit IKK-γ67. The active form of NF-κB diffuses 
through the nuclear membrane to act as a transcription factor in the nucleus68. 
Theoretically the intake of nutrients can therefore lead, via the production of 
ROS, to increased inflammatory cytokine production. Mononuclear cells from 
human individuals subjected to a single dose of 75 gram glucose showed 
increased NF-κB binding69. This could result in increased production of pro-
inflammatory cytokines in leucocytes or adhesion molecules in endothelial 
cells. Obesity, which is associated with chronic excessive nutrient intake, could 
therefore via ROS production result in low-grade inflammatory state. Cells can 
become insensitive to insulin in a low-grade inflammatory environment. 
Decreased energy intake accompanying weight loss (with or without the aid of 
surgical interventions) could therefore be one of the underlying mechanisms by 
which weight loss improves insulin sensitivity. Further research studying 
inflammatory cytokines after nutrient intake are needed to clarify this subject. 
ER-stress is another mechanism by which increased nutrient intake can lead to 
IR. The Endoplasmatic Reticulum (ER) provides an environment in which newly 
formed proteins are processed. The function of this organelle can be regulated 
via a negative feedback loop called the unfolded protein response. If the ER is 
stressed, e.g. by increased input of proteins that have to be processed, more 
proteins are misfolded or unfolded. Such proteins trigger the unfolded protein 
response, which inhibits protein synthesis and promote protein breakdown70. 
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Recently ER-stress and the unfolded protein response have been linked to IR 
and obesity. Markers of ER-stress are increased in obese mice. Obesity is 
thought to increase the metabolic workload for the cell, resulting in 
accumulation of reactive oxygen species, fatty acids and other intermediary 
metabolites which activates the unfolded protein response. The serine kinase 
c-Jun amino terminal kinase (JNK1) is a key molecule in the association 
between ER-stress and insulin resistance. This protein facilitates the serine 
phosphorylation of the insulin receptor substrate-1 suppressing insulin 
signaling and is also activated in ER-stress71. In this study no evidence of 
ER-stress was found in muscle and β-cells, only hepatic and adipose tissue 
displayed ER-stress in obesity.  
Increased nutrient intake could therefore both via activation of the NF-κB 
pathway and ER-stress lead to IR. In this context weight loss induced by 
decreased intake of nutrients could result in decreased activation of the NF-κB 
pathway and reduced ER-stress. 
Intracellular lipid accumulation 
Apart from supplying the “building blocks” of phospholipids, glycolipids and 
hormones, fatty acids serve as fuel molecules used by cells in the body. 
Obesity and T2DM are associated with increased concentration of plasma fatty 
acids72,73. The main storage organ for fatty acids is adipose tissue where large 
quantities are stored as triglycerides. Other cells also are capable of storing 
triglycerides, but their capacity is very limited. T2DM is associated with 
conditions where the storage capacity of cells for fatty acids is exceeded e.g. 
obesity or lipodystrophy. Thus T2DM developed in individuals in which the 
storage capacity of adipose tissue for triglycerides is exceeded. 
Based on the observation that increased intracellular triglyceride content 
disrupts β-cell function of the pancreas the lipotoxicity hypothesis was 
postulated74,75. Besides the pancreas, muscle and liver tissue also play a major 
role in the pathogenesis of IR. Weight loss results in decreased accumulation 
of fatty acids in these organs76,77. In the following paragraph the effects of lipid 
accumulation in pancreas, liver and muscle are discussed to clarify the role of 
decreased intracellular accumulation of lipids in the increased sensitivity to 
insulin. An overview is given in Figure 2.2. 
Pancreas 
Lipotoxicity is thought to play a central role in decreased insulin secretion of 
β-cells. Fatty acids are reported to inhibit glucose stimulated insulin release in 
isolated rat β-cells75. Furthermore, lipid infusion in normal rats inhibited 
glucose-induced insulin release78.  
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Accumulation of fatty acids by β-cells causes apoptosis. Fatty acids lead in 
vitro to apoptosis of isolated human β-cells, possible via ceramides79,80. 
Moreover, a synergistic action of glucose and fatty acids is reported on 
apoptosis in β-cells. The extent of fatty acid induced cell death and the 
magnitude of caspase activation increases with increasing glucose concen-
trations81. Another mechanism by which fatty acids can alter β-cell function is 
the loss of pancreas duodenum homebox-1 gene regulation, decreasing insulin 
promoter activity and therefore decreasing insulin secretion82,83. 
Besides lipids hyperglycemia also has dysregulating effects on β-cells. 
Hyperglycemia leads to decreased insulin secretion by the pancreas. Proposed 
mechanisms are increased oxidative stress caused by increased oxidation of 
glucose combined with naturally low levels of antioxidants (GSH, superoxide 
dismutase)84. Moreover, it is hypothesized that hyperglycemia is a requirement 
for lipotoxicity to occur85. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Pathways involved in obesity induced diabetes. 
 Obesity leads to increased accumulation of metabolites of fatty acids in cells. 
Moreover, obesity is associated with increased inflammatory parameters like TNF-α. 
Furthermore, postprandial hyperglycemia, hyperinsulinemia and oxidative stress are 
reported in obesity. LCFA-CoA and diacylglycerol increase expression of PKC θ, β and 
δ, which can directly via serine kinases or indirectly through JNK-1 and IKK-β 
activation increase serine phosphorylation of the IRS-1. TNF-α and ER-stress lead 
through JNK-1 to IRS-1 serine phosphorylation. 
 IRS-1 which is serine phosphorylated can not activate PI3 kinase. Therefore GLUT-4 
controlled glucose transport is impaired. 
 PKC: PhosphoKinase C, JNK-1: c-Jun NH-terminal Kinase-1, IKK-β: Inhibitor of 
KappaB Kinase-β, IRS-1: Insulin Receptor Substrate-1, LCFA-CoA: Long Chain Fatty 
Acyl-CoA, ER: Endoplasmatic Reticulum, PI3: PhosphInositol-3, GLUT-4: Glucose 
Transporter-4. 
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Liver 
Obesity is associated with increased accumulation of lipids in hepatocytes. 
Fatty liver is defined when deposition of fat in the liver accounts for more than 
5% of liver weight or when more than 3% of hepatocytes are affected86. IR has 
been proposed to be a cause and a consequence of non alcoholic fatty liver 
disease (NAFLD). The causative hypothesis is founded on the observation that 
many patients with NAFLD are hyperinsulinemic. Moreover, NAFLD is found in 
IR and metabolic syndrome even if patients are not suffering from T2DM and 
are not obese87,88. NAFLD has also been reported in patients with 
lipodystrophy89. NAFLD is thought to evolve in non alcoholic steatohepatitis 
(NASH) via a two-hit model. Firstly IR of hepatocytes causes triglycerides to 
accumulate in hepatocytes. Increased oxidative stress and increased influx of 
pro-inflammatory cytokines are considered the second hit90. IR and increased 
mass of the visceral fat depot are thought to play an important role. Increased 
flux of fatty acids and cytokines arising from the visceral fat depots reach the 
liver directly via the portal vein.  
On the other hand other groups have shown that hepatic IR is a consequence 
of hepatic steatosis91-93. Rats fed a high fat diet for three days develop hepatic 
steatosis. Moreover, they develop hepatic IR in the absence of peripheral IR92. 
When hepatic fat accumulation was pharmacologically prevented the high fat 
diet did not result in hepatic IR91. Fatty acids are thought to decrease insulin 
sensitivity through serine phosphorylation of the insulin receptor substrate-1. In 
hepatocytes IKK-β plays an important role in the pathway leading to serine 
phosphorylation94. Salicylates are IKK-β inhibitors and this mechanism is 
thought to explain the beneficial effects of salicylate treatment on T2DM56-58. 
Weight loss is reported to decrease NAFLD76. Hypothetically, decreased 
accumulation of lipids in hepatocytes increases insulin sensitivity which could 
lead to decreased gluconeogenesis and increased insulin clearance. 
Muscle 
Obesity is associated with increased amounts of triglycerides in muscle 
tissue95. These intramyocellular triglycerides (IMTG) are located near the 
mitochondria. It has been proposed that impaired capacity to oxidize fatty acids 
causes an increase in intracellular triglycerides content. The amount of IMTG 
was positively correlated with IR96,97. Besides increased oxidative stress as 
described in β-cells, other pathways leading to insulin sensitivity are described. 
In the 1960’s Randle proposed a theory called the Randle cycle, which was the 
first to link intracellular fatty acids to IR98-100. This theory was based on the 
observation that glucose and fatty acids compete for substrate oxidation in rat 
heart muscle. The mechanism they proposed starts with increased oxidation of 
fatty acids resulting in increase acetyl CoA/CoA and NADH/NAD+ ratios. This 
34⏐Chapter 2 
on its turn inactivates the enzyme pyruvate dehydrogenase, resulting in 
accumulation of citrate. High intracellular levels of citrate could hypothetically 
inhibit the enzymatic activity of phosphofructokinase leading to increased 
intracellular glucose-6-phosphate levels. Increased levels of glucose-6-
phosphate inhibit hexokinase II. Consequently intracellular glucose concen-
trations increase inhibiting glucose uptake. Randle and coworkers proposed 
that this mechanism links obesity to IR. 
Recently this hypothesis was questioned. It was postulated that metabolites of 
fatty acids which accumulate in the cell inhibit insulin signaling. This can result 
in failure of GLUT-4 to facilitate glucose transport. Long chain fatty acids-CoAs 
and diacylglycerol more than ceramides and triglycerides activate protein 
kinase Cθ, Cδ or βII. These kinases in turn potentiate serine/threonine 
phosphorylation of the insulin receptor and insulin receptor substrate-1. 
Moreover, tyrosine phosphorylation of the insulin receptor is inhibited. The 
increased serine/threonine and decreased tyrosine phosphorylation leads to 
dysfunctional insulin signaling preventing phosphoinositol-3-kinase activation 
leading to failure of GLUT-4 to facilitate glucose transport101-104. 
Weight loss results in decreased IMTG. Also the intracellular long chain fatty 
acid-acyl-CoA concentration, which is related to IR, decreases. Moreover, 
weight loss improves insulin sensitivity increasing tyrosine phosphorylation of 
insulin receptor substrate-1105,106. Both the induction of IR by intracellular lipids 
and the decreased intracellular lipid amount caused by weight loss support the 
hypothesis that an important mechanism in IR in muscle includes lipid 
accumulation inside myocytes. 
Decreased fat mass 
Adipokines 
Adipose tissue is no longer solely considered to be a fat-storing organ. The 
observation that adipose tissue could secrete TNF-α was the first to directly link 
adipose tissue to IR. In the years to follow different adipokines were discovered 
and many of them play a role in the etiology of IR.  
In 1993 TNF-α was found to be expressed in adipose tissue of rodents107. Later 
this finding was confirmed in human adipose tissue108,109. These observations 
linked obesity to IR. TNF-α is thought to play a causative role in the 
development of IR, rendering target tissues like adipose tissue insensitive for 
insulin110-112. Additionally, circulating TNF-α plasma levels are increased in 
obese individuals37,113. The possible mechanisms by which TNF-α decreases 
insulin sensitivity include increased serine phosphorylation of the insulin 
receptor and down regulation of GLUT-4 expression110-112. Moreover, TNF-α is 
thought to act as an adipostat reducing triglyceride content in adipocytes which 
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reach their storage threshold114. TNF-α inhibits lipoprotein lipase activity, 
preventing fatty acids uptake into the adipocyte. Furthermore, the hormone 
sensitive lipase activity in adipocytes is increased under the influence of 
TNF-α115,116. These findings stress the importance of TNF-α in the 
pathogenesis of IR. However, treatment of diabetic patients with antibodies 
directed against TNF-α does not lead to increased insulin sensitivity in diabetic 
patients117.  
Plasma Interleukin (IL-6) originates for 30% from adipocytes118. It is thought 
that IL-6 production by visceral fat induces CRP production by the liver. This is 
seen as the main cause for increased CRP levels in obese individuals119. IL-6 
was reported to decrease activation of insulin substrate-1 and phosphoinositol 
3 phosphate kinase120,121. Administration of recombinant IL-6 in animal models 
as well as humans induced hepatic gluconeogenesis122. These results indicate 
that IL-6 can cause IR. 
Adiponectin is produced by adipocytes, but in contrast to e.g. leptin does not 
increase in obesity. Obesity and T2DM are associated with decreased 
adiponectin levels123,124. The role of adiponectin in IR is multifactorial. 
Adiponectin decreases hepatic glucose output in animal studies and is 
associated with hepatic glucose output in humans125-127. Moreover, 
administration of adiponectin in mice treated with LPS resulted in decreased 
TNF-α plasma levels128. In addition, human macrophages treated with 
adiponectin show decreased TNF-α and IL-6 production129. On the other hand, 
TNF-α was reported to decrease adiponectin secretion of isolated human 
adipocytes130. 
Resistin was formerly seen as the molecule linking obesity to IR. In animal 
studies resistin concentrations are associated with IR and infusion of 
recombinant resistin causes hepatic IR. Furthermore, glucose tolerance is 
impaired in wild type mice given recombinant resistin131. The former 
enthusiasm towards resistin has somewhat been tapered off. In humans the 
close association between IR and resistin levels does not exist132. However, 
plasma resistin levels are reported to be associated with waist-hip ratio and 
body fat mass133. The major production site of resistin in man are 
monocytes134. Resistin production is induced by inflammatory mediators like 
TNF-α and LPS and can on its turn induce TNF-α and IL-12 production from 
macrophages135-137. This leads to the hypothesis that resistin plays a central 
role in IR associated with sepsis and other inflammatory conditions.  
Weight loss results in decreased plasma levels of TNF-α or its receptors and 
IL-637,113,138. In addition, TNF-α mRNA expression in adipose tissue decreased 
after weight loss139. Plasma adiponectin levels as well as adiponectin mRNA 
derived from adipose tissue increased after weight loss140,141. 
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Macrophage accumulation 
With increasing BMI macrophages accumulate in adipose tissue142,143. These 
adipose tissue resident macrophages could potentially play a role in the status 
of low-grade inflammation of obesity induced IR. Specific macrophage IKK-β 
knockout mice are protected against IR induced either by inflammation or a 
high fat diet144. Weight loss results in decreased numbers of macrophages145. 
Moreover, treatment of individuals with impaired glucose tolerance with the 
insulin sensitizing agent pioglitazone reduced CD68 mRNA expression in 
adipose tissue146. Further studies are needed to elucidate if the accumulation 
of macrophages has any pathophysiological consequences. 
Summary 
Bariatric surgery is the treatment of choice for individuals with a BMI over 
35 kg/m2 with co-morbidities or a BMI over 40 kg/m2. Bariatric surgery is also 
effective in treating T2DM in morbid obese individuals. The immediate effect of 
biliopancreatic diversion and gastric bypass on insulin sensitivity led to 
hypotheses regarding gut hormones. Exclusion of part of the gut and 
consequently absence of food in the foregut could reduce the production of GIP 
via the decreased secretion of an anti-incretin by the foregut. More plausible is 
the hypothesis that due to the bypass of nutrients, the distal ileum receives 
increased amounts of unprocessed nutrients. This could result in increased 
GLP-1 plasma levels, increasing insulin sensitivity. 
The effect of bariatric surgery on gut hormones can not solely explain the effect 
on T2DM. Bariatric surgery also results in decreased nutrient intake, decreased 
intracellular fatty acid load and decreased fat mass. These behavioral and 
metabolic changes could underlie the success of bariatric surgery in treating 
T2DM. Caloric restriction resulted in decreased formation of ROS and therefore 
could decrease the low-inflammatory state. Decreased accumulation of lipids in 
the pancreas improves β-cell functioning. Moreover, in myocytes and 
hepatocytes the intracellular pathway of insulin signaling is less impaired. In 
addition, decreased fat mass induced by weight loss results in alterations in 
plasma levels of adipokines. Furthermore, the number of macrophages in 
adipose tissue decreased after weight loss. Prodiabetogenic factors TNF-α and 
IL-6 levels decreased whereas the insulin sensitizing adipokine adiponectin 
increased after weight loss.  
Future directions 
The International Federation for the Surgery of Obesity (IFSO) guidelines 
regarding bariatric surgery state that bariatric surgery is reserved to obese 
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individuals with a BMI over 35 kg/m2 with serious co-morbidities and individuals 
with a BMI over 40 kg/m2. Recently O’Brien proposed to lower this BMI border. 
In a randomized clinical trial they included patients with BMI ranging from 30-35 
and found that patients were able to decrease their bodyweight more effectively 
than using conventional treatment. Moreover, quality of life and measures of 
the metabolic syndrome showed more improvement in the surgically treated 
group147. The observation that moderately obese patients with T2DM could 
also benefit from surgery initiates the discussion that these patients should be 
taken into consideration for bariatric surgery.  
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Abstract 
Background 
Ghrelin is a recently discovered orexigenic gastric hormone, which production is induced by the 
lack of food in the stomach. In morbidly obese individuals, ghrelin levels are low compared to lean 
persons. During dieting plasma ghrelin levels increase, leading to an orexigenic signal which could 
explain the lack of success of dieting in morbidly obese patients. Morbid obesity is best treated with 
bariatric surgery of which gastric bypass surgery is reported to be more effective than restrictive 
surgery. A possible explanation could be the difference in plasma ghrelin levels after both 
techniques of bariatric surgery. In this study plasma ghrelin levels are investigated during a two 
year follow-up. 
 
Methods 
Seventeen morbid obese patients received restrictive surgery. Plasma ghrelin, leptin and insulin 
levels were evaluated preoperatively, one year and two years postoperatively. 
 
Results 
BMI decreased from 47.5±6.2 kg/m2 to 33.2±5.8 kg/m2 (p<0.001). Plasma ghrelin levels were 
significantly increased one year (p<0.05) and two years (p<0.02) postoperatively. Fasting plasma 
leptin and insulin levels were significantly lower at two years after surgery (p<0.001). 
 
Conclusion 
After restrictive surgery ghrelin levels increased, this in contrast to the reported fall in ghrelin levels 
after gastric bypass surgery. This difference in ghrelin levels between these operative techniques 
can be the key to understanding the superiority of gastric bypass in sustaining weight loss 
compared to restrictive surgery. 
 Ghrelin, leptin and insulin after restrictive bariatric surgery⏐49 
Introduction 
Via receptors present in the arcuate nucleus of the hypothalamus satiety 
hormones influence a feedback mechanism that controls energy intake. These 
receptors are situated on the catabolic proopiomelanocortin (POMC) and 
anabolic neuropeptide-Y/Agouti related protein (NPY/AgRP) neurons. The 
catabolic neurons are activated by leptin as well as insulin and suppressed in 
states of genetically defective leptin signaling. In response to leptin POMC is 
cleaved into melanocortins of which receptors are present in brain areas that 
regulated food intake and autonomic activity. The anabolic neurons are 
stimulated by ghrelin and suppressed by leptin and insulin. This explains the 
orexigenic effect of ghrelin and the satiety inducing property of leptin and 
insulin1. These and other feedback mechanisms balance food intake and 
energy expenditure.  
Ghrelin is a 28 amino acids peptide with strong Growth Hormone (GH) 
releasing activity and is mainly produced by the X/A like cells of the oxyntic 
glands in the fundus of the stomach which are nowadays referred to as ghrelin 
cells or Gr cells. Production of ghrelin is attenuated by the presence and 
stimulated by the absence of food in the stomach2,3. In rats ghrelin acts 
orexigenic: administration of ghrelin results in increased food intake4. Other 
actions are inhibition of insulin producing β- and somatostatin producing D-cells 
in the pancreas5. 
In the morbidly obese individual satiety regulating mechanisms are disturbed, 
leptin and insulin levels are high and ghrelin levels are low6,7. Non invasive 
methods used to treat morbid obesity as weight reduction achieved by 
exercise, medical therapy and dieting, usually does not result in long term 
weight loss8. This is thought to be caused by increasing ghrelin and decreasing 
leptin levels resulting in strong orexigenic signals after weight loss9. Bariatric 
surgery is far more effective in maintaining weight loss with loss of excess 
weight as high as 50-70%10. Compared to restrictive surgery patients treated 
with gastric bypass surgery are less hungry, eat fewer meals and reduce the 
intake of high calorie food voluntarily11. It is suggested that this is not due to the 
gastric restriction alone but also to a decline in ghrelin levels post-
operatively9,12. After gastric bypass surgery the main producer of ghrelin, the 
stomach, receives no food. Paradoxically, in contrast to the high plasma ghrelin 
levels expected in these patients, low ghrelin levels are found, maybe as a 
result of exhaustion of the Gr cells. In patients treated with restrictive bariatric 
surgery, the stomach still receives food, although to a lesser extent. We 
therefore hypothesized that in the long term restrictive bariatric surgery results 
in a rise in ghrelin levels, giving the patient an orexigenic signal. 
50⏐Chapter 3 
Patients and methods 
In total 17 subjects who were admitted to the Surgical Department of the 
University Hospital Maastricht to undergo an operation for morbid obesity, were 
included in the study. The group contained 14 female and 3 male individuals 
aged 44±7 years. These patients underwent a primary operation for morbid 
obesity (vertical banded gastroplasty (VBG, n=7) or LapBand® (n=10)). All 
subjects were otherwise healthy according to history, clinical examination and 
routine laboratory findings. Blood samples were collected after at least eight 
hours fasting using evacuated blood collection tubes containing EDTA at the 
day of admission to the hospital, one day before surgery. The blood samples 
were immediately put on melting ice and plasma was prepared by 
centrifugation at 1,400 g for 10 min at 4°C. The supernatants were centrifuged 
at 2,700 g for 10 min at 4°C and stored in aliquots at –80°C. All participants 
gave written informed consent. The study was approved by the local ethical 
committee of the Academic Hospital Maastricht. 
Vertical banded gastroplasty (VBG) 
The procedure was performed as described by Mason13. In short a small 
stomach pouch of approximately 15-20 ml was created with a 4-row linear 
stapler (TA-90B) precisely to the angle of His and a Dacron band of 5.0 cm in 
circumference, placed through the window formed by a circular stapler 
(Premium Plus CEEA 31 mm, United States Surgical Corp., Norwalk, CT) 
leaving a small opening for food to pass14. 
Laparoscopic gastric banding (LapBand®) 
The LapBand® (BioEnterics, Carpinteria, CA) is made of soft silicone and 
equipped with an elastic balloon. For definitive positioning of the band a 15 ml 
calibration balloon was pulled up to the gastroesophageal junction. Under this 
balloon the band was closed and with three or four sutures the ventral aspect 
of the greater curvature of the stomach was fixed to the pouch to ensure a 
stable anterior position of the band. Six weeks postoperatively the LapBand® 
was insufflated when weight loss was insufficient (less than 6 kilogram). 
Thereafter the balloon was gradually inflated based on weight loss and food 
restriction (max. 4,5cc)15,16  
Measurements  
BSA was purchased from Sigma (St. Louis, MO). Bovine calf serum purchased 
from HyClone Laboratories, Inc. (Logan, UT) was heated at 56°C for 30 min 
before storage at 4°C. 
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Plasma concentrations of ghrelin and leptin were measured using sandwich 
ELISAs. For detection of plasma leptin levels, plates (Nunc maxisorb, Nunc, 
Roskilde, Denmark) were coated overnight at 4°C with the murine antihuman 
leptin mAb 4G1. After blocking with 1% BSA in PBS, diluted plasma samples 
and a dilution series of recombinant human leptin, the standard curve, were 
added to the plate. Recombinant human leptin was purchased from R&D 
systems (Minneapolis, MN). Bound leptin was detected by incubation with 
antihuman leptin mAb 4F8, followed by peroxidase-conjugated goat antimurine 
IgA (Caltag Laboratories, Burlingame, CA). 3,3',5,5'-tetramethylbenzidine 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD) was used as substrate for 
peroxidase, and color intensity was determined by measuring absorbency at 
450 nm. The detection limit of this leptin assay is 0.04 ng/ml. Both mAb, 4G1 
and 4F8, were kindly provided by Dr. R. Devos (Hoffmann La-Roche, Welwyn 
Garden City, UK). 
Ghrelin concentrations were measured using a competitive ELISA kit from 
Phoenix peptides (Phoenix pharmaceuticals, Belmont, CA). 
Plasma insulin levels were routinely assessed by the clinical chemistry 
laboratory of the academic hospital by means of the AutoDELPHIA automatic 
immunoassay system (Wallac, Turku, Finland). The plasma insulin assay had a 
detection limit of 3 pmol/l. 
All plasma samples were analyzed in the same run. When plasma 
concentrations exceeded the upper detection limit of the assay, samples were 
additionally diluted and analyzed in a separate run with an overlap to correct for 
inter-assay variation. The intra- and inter-assay coefficients of variance of both 
assays were <10%. 
Plasma levels of ghrelin, leptin and insulin were expressed in mean ± SEM. Pre 
and post operative results were compared using the paired student’s t-test, a p 
value less than 0.05 was considered as statistical significant. 
Results 
As expected restrictive bariatric surgery resulted in a significant loss of excess 
weight (EWL) of 61.7±24.6 % at the end of the two year follow-up. This is 
illustrated by a decrease of BMI from 47.5±6.2 kg/m2 to 33.2±5.8 kg/m2 
(p<0.01). %EWL was not influenced by the restrictive bariatric surgical 
techniques used. In accordance with our hypothesis mean ghrelin levels 
increased after bariatric surgery from 742±246 pg/ml preoperative to 
904±127 pg/ml two years postoperative (p<0.05) (Figure 3.1A). As in %EWL 
there was no correlation between the surgical technique used and difference in 
pre- and postoperative ghrelin levels. An increase of more than 40% in 
circulating plasma ghrelin levels was seen in nine out of seventeen patients, 
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whereas four patients showed minimal increased postoperative ghrelin levels, 
ranging from 1 to 26%. In four patients ghrelin levels decreased with 6, 11, 13 
and 38% respectively.  
Ghrelin has an orexigenic effect. Hypothetically a rise in ghrelin levels would 
lead to an increase in food uptake. Therefore %EWL was correlated with the 
difference in pre- and postoperative ghrelin levels. However, no correlation was 
found. 
Other factors that influence satiety are leptin and insulin. In line with the 
observed fall in BMI fasting plasma leptin levels were reduced from 
97±37 ng/ml to 48±44 ng/ml (p<0.001) during the two year follow-up period 
(Figure 3.1B). Another important hormone with similar effects as leptin on 
satiety is insulin. After two years, fasting plasma insulin levels decreased from 
26±12 IU/ml to 6±6 IU/ml (p<0.001) (Figure 3.1C). Although in literature fasting 
insulin levels are negatively correlated with fasting ghrelin levels17 in this study 
no correlation was found between preoperative insulin and ghrelin levels. 
Moreover after surgery differences in pre- and postoperative insulin and ghrelin 
levels did not correlate. 
 
A                                                              B 
 
 
 
 
 
 
 
 
                                  C 
 
 
 
 
 
 
 
 
Figure 3.1. Restrictive surgery leads to a strong increase in circulating ghrelin levels (a) and a 
decrease in plasma leptin (b) and insulin (c) levels. Values are shown as mean ± SEM. 
* p<0.05 compared to preoperative values. 
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Discussion 
As expected after restrictive bariatric surgery a decrease in BMI, excess 
weight, leptin and insulin was achieved two years postoperative. Ghrelin 
kinetics did not differ between adjustable gastric banding and VBG. Thus both 
techniques have similar effects on the amount of food ingested resulting in 
comparable stimulation of Gr cells. This study shows that circulating ghrelin 
levels rise after restrictive bariatric surgery indicating an increased ghrelin 
production by the stomach. In contrast others reported that ghrelin levels in 
patients subjected to restrictive surgery did not change after one year18. 
Another study investigating postoperative ghrelin levels revealed that one year 
after surgery ghrelin levels were higher in patients who received restrictive 
surgery than after gastric bypass surgery19. 
When different bariatric surgical techniques are evaluated, gastric bypass 
surgery compared to restrictive bariatric techniques tends to be more 
effective10,11,20. This is in line with the paradoxical finding that patients after 
gastric bypass, despite low food intake, have extremely low ghrelin 
levels9,12,21,22. The mechanism for the disparity in behavior of ghrelin after the 
different surgical techniques is not yet elucidated. Recently Cummings et al. 
postulated that after gastric bypass surgery, as a consequence of the lack of 
food in the excluded stomach, a continuous stimulation of the ghrelin producing 
Gr cells occurs. This leads to an exhaustion of the Gr cells, resulting in very low 
circulating ghrelin levels, a hypothesis called the override inhibition theory9. 
These low levels of ghrelin after gastric bypass surgery could result in 
increased satiety. As shown here ghrelin levels rise after restrictive bariatric 
surgery. A possible explanation could be that in restrictive bariatric surgery 
passage of food through the stomach, although to a lesser extent, is still taking 
place. Gr cells are not exhausted and react with an increased production of 
ghrelin which could result in increased appetite in patients after restrictive 
surgery. 
Ghrelin however is not the only satiety regulating hormone. Leptin and insulin 
reduce satiety, but in morbidly obese patients signaling functions of both 
hormones are considered to be defective1. Gastric bypass surgery leads to 
reduced circulating leptin and insulin concentrations22. This study, as well as 
other studies19,23, shows that also after restrictive surgery circulating leptin and 
insulin levels strongly decreased. Taken together the difference in effect 
between gastric bypass and restrictive surgery is only reflected by the 
difference in ghrelin levels, emphasizing the potential role of ghrelin. However 
one should bear in mind that no correlation was found between %EWL and the 
difference in pre- and postoperative ghrelin levels, indicating that postoperative 
regulation of food intake is under the influence of multiple factors which still 
need investigating. 
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In conclusion, in contrast to gastric bypass surgery, restrictive surgery leads to 
increased ghrelin levels which can be responsible for the superior effect of 
gastric bypass surgery. These results indicate that attention should be paid to 
the association between plasma ghrelin levels and efficacy of bariatric surgery. 
Surgical techniques bypassing the stomach as well as adding ghrelin lowering 
medication after restrictive surgery can increase satiety and thus contribute to a 
more successful treatment to conquer morbid obesity. 
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Abstract 
Leptin protects the organism for an energy deficit and can no longer be seen as a hormone which 
could be used therapeutically to prevent an energy surplus. However leptin may still have an 
impact in clinical medicine. Leptin was shown to have several important functions. The pleiotropic 
properties of leptin include a regulatory function in the immune system. Reviewing the effects of 
leptin on different parts of the immune system learns that the immune system is deregulated in an 
environment low in leptin. A strong reduction in leptin levels occurs in situations of starvation as 
seen after bariatric surgery. We postulate the hypothesis that the starvation induced postoperative 
decrease of leptin is causative to the more serious course of complications observed after bariatric 
surgery. 
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Introduction 
Approximately 30 years ago two genes believed to play a role in the 
development of obesity were discovered. They were called the ob and db 
genes. Mice lacking either the ob or the db gene (ob/ob and db/db mice), 
develop severe obesity1. By means of parabiotic experiments it became clear 
that db/db mice synthesize the molecule that ob/ob mice lacked, whereas 
db/db mice are unable to respond to this molecule. It was hypothesized that the 
molecule coded for by the ob gene is a satiety factor which acts on a receptor 
encoded by the db gene. It lasted till the mid nineties until this molecule was 
identified. Friedman and co workers cloned the ob gene that encoded for a 
16kDa protein named leptin (Greek: leptos = thin)2. Treatment of ob/ob mice 
with leptin reduced body weight and increased activity. Leptin appeared to be 
mainly produced by adipocytes which explains the strong correlation between 
circulating leptin levels and BMI3.  
The receptor for leptin was discovered shortly after the discovery of the ligand. 
The leptin receptor is a single membrane-spanning receptor related with the 
gp130 signal-transducing component of the IL-6 receptor4. In total six isoforms 
are currently described, obRa, Rb, Rc, Rd, Re and Rf. The obRe is a soluble 
receptor which is though to have a regulating function by controlling plasma 
leptin levels3,5. Ra-Rd and Rf are membrane bound receptors with similar 
extracellular and transmembrane domains. Only one isoform, the obRb, which 
has a long intracellular domain (306 amino acids), is considered to be the 
principal signaling molecule. However, there is suggestive evidence that short 
forms also have a signaling function6. 
It is hypothesized that leptin via leptin receptors present in the arcuate nucleus 
of the hypothalamus can enhance the negative feedback mechanism which 
results in a decrease of energy intake. These receptors are situated on the 
catabolic proopiomelanocortin (POMC) and anabolic neuropeptide-Y/Agouti 
related protein (NPY/AgRP) neurons7. POMC is cleaved into melanocortins 
which receptors are present in brain areas that regulate food intake and 
autonomic activity. The catabolic neurons are activated by leptin and 
suppressed in states of genetically defective leptin signaling. The anabolic 
neurons are suppressed by leptin and activated in states of genetically 
defective leptin signaling8 (illustrated in Figure 4.1). These data led to the 
general acceptation of the hypothesis that leptin acts as satiety factor. 
Leptin treatment of extremely obese and hyperphagic leptin deficient mice 
resulted in more active behavior, less food intake as well as weight loss in 
these animals. However, the crucial difference between the experimental leptin 
deficient mouse and the obese patient is the absence of circulating leptin in 
leptin deficient mice versus high levels of leptin in obese individuals. In parallel 
with insulin resistance it was hypothesized that morbid obese patients are 
60⏐Chapter 4 
leptin resistant, with the db/db mice (lacking the long form of the leptin 
receptor) as an ultimate model. Unfortunately, in contrast to diabetes, in which 
insulin resistance can be treated by administration of excess insulin, 
administration of excess leptin does not result in substantial weight loss. Some 
articles describe weight stabilization or weight loss after leptin treatment in 
humans9. This effect however is minor and immediately reversed after 
cessation of the treatment. Currently the role of leptin is therefore no longer 
sought in preventing an energy surplus but in protecting the organism in 
situations of an energy deficit as seen in starvation10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Regulation of satiety by leptin 
 
 
Recently an additional role for leptin was postulated. Several authors described 
the resemblance of the immunological status of leptin deficient mice with that of 
starved wild type mice. The immunological abnormalities  include impaired 
T-cell responses and thymic atrophy, which render these mice more 
susceptible to infections11. A parallel situation is seen in leptin deficient humans 
and patients suffering from anorexia nervosa12. Leptin deficient subjects are 
hyperphagic and therefore obese, whereas the low leptin levels seen in 
anorexia nervosa are due to fasting. Both subjects however have absent (leptin 
deficiency) or very low (starved) leptin levels, therefore a role for leptin and not 
solely the obesity status in the immune system is hypothesized. These findings 
shift our attention from the metabolic to the immunologic aspects of leptin. 
Especially in conditions where leptin levels are low or decreasing fast. 
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Leptin is of interest for bariatric surgery because of its property to act as an 
acute phase protein. The molecular structure of leptin resembles that of the 
Interleukin-6 (IL-6) cytokine family13. Leptin however can by itself not induce an 
acute phase response like IL-614. In animal models of acute inflammation as 
well as in septic patients and postoperative patients, leptin levels are 
increased15-19. The rise in leptin levels can be a direct result of increased levels 
of lipopolysaccharide (LPS), Tumor Necrosis Factor alpha (TNF-α) and IL-1, 
since both LPS and these cytokines induce leptin production20-25. 
Which implication has the hypothesis that leptin functions as an acute phase 
protein for bariatric surgery? Directly after bariatric surgery, leptin appears to 
act as a positive acute phase protein. However, within 48 hours the leptin 
levels decreased26-28. Suppression of the immune system as seen in patients 
suffering from anorexia nervosa (low leptin) and in leptin deficient mice (absent 
leptin) raises the question whether the strong decrease in leptin levels 
postoperatively could play a role in the pathogenesis of postoperative 
complications observed after bariatric surgery29. 
Subjects and methods 
Subjects and samples 
All participants gave written informed consent. The study was approved by the 
local ethical committee of the Academic Hospital Maastricht. 
A total of fifteen subjects admitted to the Surgical Department of the University 
Hospital Maastricht to undergo an operation for morbid obesity, were included 
in the study. The group comprised fourteen females and one male aged 37±6 
years with a mean BMI of 49.7±4.3 kg/m2. These patients underwent a primary 
operation for morbid obesity (Vertical banded gastroplasty (VBG, n=11) or 
laparoscopic gastric banding using Lap-Band (n=4)). All subjects were 
otherwise healthy according to history, clinical examination and routine 
laboratory findings.  
Blood samples were collected after at least eight hours fasting using evacuated 
blood collection tubes containing EDTA one day before surgery, and 24, 48 
and 72 hours after surgery and processed as previously described30. 
Leptin immunoassay 
Plasma concentrations of leptin was determined using sandwich ELISA. For 
detection of plasma leptin levels plates (Nunc maxisorb, Nunc, Roskilde, 
Denmark) were coated overnight at four degrees Celcius with the murine 
antihuman leptin mAb 4G1. After blocking with 1% BSA (Sigma, St. Louis, MO) 
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in PBS, diluted plasma samples and a dilution series of recombinant human 
leptin, the standard curve, were added to the plate. Recombinant human leptin 
was purchased from R&D systems (Minneapolis, MN). Bound leptin was 
detected by incubation with antihuman leptin mAb 4F8 followed by peroxidase-
conjugated goat antimurine IgA (Caltag Laboratories, Burlingame, CA). 
3,3',5,5'-tetramethylbenzidine (Kirkegaard & Perry Laboratories, Gaithersburg, 
MD) was used as substrate for peroxidase, and color intensity was determined 
by measuring absorbency at 450 nm. The detection limit of this leptin assay is 
0.04 ng/ml. Both mAb, 4G1 and 4F8, were kindly provided by Dr. R. Devos 
(Hoffmann La-Roche, Welwyn Garden City, UK).  
All plasma samples were analyzed in the same run. The intra- and inter-assay 
coefficients of variance of the various assays were <10%. 
Statistical analysis  
All data are expressed as median with interquartile range. Due to the non-
parametrically distributed data, preoperative and postoperative results were 
compared using repeated measurements ANOVA (analysis of variance). A p-
value less than 0.05 was considered statistically significant. 
Results 
Leptin levels where not increased at 24 hours after surgery. However, similar to 
previous studies a decrease in leptin was observed after three days in fourteen 
of the fifteen patients studied. Of these patients about 75% showed a decrease 
of more than 45%. During the first three days, postoperative median leptin 
levels decrease from 77.8 ng/ml (1st quartile: 60.3, 3rd quartile: 105.0) to 
38.0 ng/ml (1st quartile: 25.1, 3rd quartile: 61.0) (p<0.001) (Figure 4.2). Normally 
plasma levels of 38 ng/ml correlate with a BMI of about 303. BMI did not 
change during the first three days, indicating that in the postoperative period 
leptin is not simply a reflection of fat mass or BMI. 
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Figure 4.2. Leptin levels decrease rapidly after bariatric surgery. Leptin levels preoperative and 72 
hours postoperative of 15 morbid obese patients are given. *: p<0.05. 
Discussion 
Inflammation and infection are part of the pathogenesis of most of the early 
postoperative complications like pulmonary emboli, wound infection and sepsis, 
suggesting that the immune system plays an essential role in the pathogenesis. 
Particularly in the context of postoperative septic complications, which have a 
more severe course in morbid obese patients compared to lean patients. A 
statement however, which is based on general surgical opinion and not on 
published studies. During the first days after bariatric surgery it is important to 
focus on the pleiotropic properties of leptin. Starvation leads to a rapid 
decrease of circulating leptin levels. This decrease in leptin, reflecting the 
metabolic state of the individual, results in a relative leptin deficiency which 
may cause a deregulation of the immune system.  
We postulate that during the first two days postoperative, surgical stress and 
starvation have opposing effects on circulating leptin levels. Starvation leads to 
a decrease in leptin whereas surgical stress increases leptin31,32. After the 
second day of bariatric surgery, starvation dominates; the result is that the 
individual has to cope with a sharp decrease in leptin levels. 
Leptin deficiency makes an organism more susceptible to septic shock, 
induced by LPS33. Administration of leptin to deficient mice reversed this 
vulnerability. Another study reported that leptin deficient mice are also 
vulnerable to LPS induced hepatotoxicity34. Interestingly, the LPS induced 
mortality of mice lacking the leptin receptor (db/db mice) resembled that of wild 
type mice, despite the fact that they are as obese and diabetic as leptin 
deficient mice35. An explanation for this paradoxical finding may be the 
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presence of soluble leptin receptors in db/db mice. These receptors, when 
bound to leptin, can translocate to the membrane and trigger intracellular 
cascades, while signaling in the central nervous system is absent6,36. 
Leptin deficient, db/db as well as wild type mice pretreated with leptin 
antagonists were more susceptible to the lethal toxicity of TNF-α compared to 
wild type mice. Furthermore, leptin deficient mice treated with exogenous leptin 
were protected against the lethal toxicity of TNF-α. Thus in a leptin deficient 
environment TNF-α is more toxic than in a normal environment, which can be 
reversed by administrating leptin37. 
Taken together this leads to a hypothesis that leptin protects the organism 
against the auto-aggressive effects of the immune system. During sepsis 
increased leptin levels induced by mediators like TNF-α, IL-1 and/or LPS20-24, 
may be involved in counteraction of the harmful effects of pro-inflammatory 
cytokines. The finding that higher leptin levels in septic patients are significantly 
related to a higher chance of survival supports this hypothesis17. The regulatory 
role of leptin on the cellular level is illustrated by the finding that macrophages, 
polymorphnuclear cells (PMN’s) and natural killer cells (NK-cells) express the 
short (ob-Ra) and long (ob-Ra) leptin receptor38-43. Phagocytotic activity of 
macrophages from lean non-diabetic mice is enhanced by adding leptin39. In 
line with this observation is the reduced phagocytic function of macrophages in 
animals with low or absent leptin levels44,45. This also accounts for situations 
were leptin signaling is impaired by absence of leptin receptors44. 
Administration of leptin abrogated this difference in ob/ob mice (lacking leptin) 
but not in db/db mice (lacking the ob-Rb receptor). This makes it plausible that 
leptin acts directly via ob-Rb on macrophages to improve phagocytic 
functioning. Compared to wild type mice leptin deficient mice are more 
vulnerable to LPS induced hepatotoxicity34. A further role for leptin in NK cell 
physiology was recently established. Tian et al. observed that in db/db mice the 
total number of NK-cells in spleen, liver, peripheral blood and lung was 
reduced, while the NK-cells expression of CD69 (activation marker) was lower 
both at baseline and after poly I:C stimulation and activation. Leptin treatment 
of NK-cells of wild type mice increased both their basal and IL-15 or poly I:C 
stimulated lysis of splenocytes. A phenomenon absent in spleens of db/db 
mice46. Leptin  also enhanced expression of indicators of NK-cell activity, such 
as IL-2 and perforin genes transcription of human NK-cells, further 
emphasizing the importance of leptin for normal NK-cell functioning43. Leptin 
enhances the oxidative and chemotactic response of human neutrophils in 
vitro42,47. Hypothetically leptin deficiency leads to less production of reactive 
oxygen species (ROS) by PMNs. As a consequence an organism deficient in 
leptin will be less capable of killing bacteria by ROS production and 
subsequently more susceptible to invading micro-organisms. 
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Pretreatment of murine macrophages with leptin results in higher LPS induced 
IL-6, IL-12 and TNF-α production, while leptin on itself was not capable to 
induce cytokine release44. In contrast, stimulation of human monocytes with 
leptin in absence of LPS led to increased TNF-α and IL-6 production41,48. In line 
with these observations macrophages obtained from calorie restricted mice, 
which have low circulating leptin levels, released less IL-6 and IL-12 after LPS 
stimulation49,50. Leptin deficient mice respond to LPS stimulation with lower 
plasma TNF-α and IL-6 levels, compared to wild type mice44,49. In the same 
experiments, plasma levels of the anti-inflammatory cytokines IL-10 and IL-1Ra 
were also lower in leptin deficient mice. The latter was confirmed by stimulation 
of murine monocytes (RAW cell line) with both LPS and leptin, resulting in an 
increased IL-1Ra production33,38. These results lead to the question why leptin 
deficient mice, which produce less TNF-α, are not protected from LPS induced 
mortality. Normal mice are thought to die from LPS by large amounts 
circulating of proinflammatory mediators like TNF-α. A possible explanation for 
this paradoxical finding can be that the decreased IL-1Ra and IL-10 release 
renders the leptin deficient mouse more vulnerable even to lower doses of 
TNF-α. This is supported by the finding that leptin deficient or db/db mice are 
more vulnerable to exogenous TNF-α administration37. Other groups have 
found contrasting data, showing increased TNF-α levels at baseline in leptin 
deficient an db/db mice as well as after stimulation by LPS or Cecal Ligation 
and Puncture (CLP) in starved wild type mice49,51,52. At this stage there is no 
explanation for these contrasting results. However, in line with the experiments 
discussed in this paragraph, also these mice were more susceptible to LPS or 
CLP induced septic shock. 
Not only the innate immunity responsible for the acute phase reaction but also 
the aquired immunity is affected by leptin. Lymphocytes express the functional 
leptin receptor, which indicates that leptin can have an effect on these cells53,54. 
A deficient T-cell function is seen in leptin deficient mice, which is corrected 
after leptin administration. This T-cell dysfunction is illustrated by a reduced 
delayed type hypersensitivity, thymic atrophy and a lower number of circulating 
lymphocytes55-57. Similar defects are reported in humans who lack the ob 
gene12. Farooqi et al. showed that leptin deficiency leads to a complete 
suppression of the Th1 immune response and to a lesser extent suppression of 
the Th2 response58. In conditions in which leptin levels are low but not absent, 
like in starvation, plasma levels of IL-4 are increased, indicating a dominance of 
the Th2 immune response59,60. This was confirmed in vitro in wild type murine 
T-lymphocytes harvested after starvation, which produce more IL-4 and less 
IFN-γ60. Currently no in vivo data exist on the effect of high plasma leptin levels 
on T-cell differentiation as seen in morbid obese individuals. In vitro data show 
that human macrophages and T-lymphocytes as well as murine T-lymphocytes 
treated with leptin react with an increased production of the Th-1 cytokines 
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IFN-γ and IL-2 and a decreased production of the Th-2 cytokine IL-441,53,54,61. 
These data suggest that in an environment abundant in leptin, Th1 cytokines 
are upregulated, while during fasting the Th2 cytokines dominate. The impact 
on the immune system of a dominant Th2 immune response during states of 
low leptin is not known, but we consider that this imbalance in Th1/Th2 status 
plays a role in the increased susceptibility to LPS, TNF-α or infection induced 
sepsis. 
Low leptin levels are unfavorable for an organism, leading to a less efficient 
innate and acquired immune response. These considerations also can be put 
in the perspective of surgery in the cachectic patient, which also have a higher 
incidence of postoperative complications62. Several studies have shown that 
leptin is decreased in cachexia as seen in cancer patients to levels as low as 
3 ng/ml63-67. Such low leptin levels can suppress the immune system and favor 
postoperative complications.  
In summary, after bariatric surgery there is an increased risk of more serious 
complications, in which the immune system plays a central role. This is the 
result of the interplay between the energy balance and the immune system, in 
which leptin is the crucial mediator. Starvation as seen after bariatric surgery, 
results in strongly reduced leptin levels. The relative loss of leptin in such 
patients is considered to impair the immune system rendering the morbid 
obese patient more prone to develop postoperative complications. This leads to 
the question whether leptin can be used as a pharmacological intervention, to 
support the immune system in the postoperative period after bariatric surgery, 
the only proven effective treatment of morbid obesity68. 
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Abstract 
Background 
Increased plasma levels of endothelial activation markers in obese subjects reflect the positive 
association between cardiovascular diseases and obesity. The pro-inflammatory state associated 
with obesity is thought to play a major role in endothelial cell activation in morbid obese individuals. 
Previous studies demonstrated that long term weight loss after bariatric surgery is accompanied by 
a decreased pro-inflammatory state. However, little is known about the long term effects of bariatric 
surgery on endothelial cell activation.  
 
Methods 
Plasma levels of sICAM-1, sE-selectin and sVCAM-1, all markers of endothelial cell activation and 
of their regulators adiponectin and resistin were measured at different time points postoperatively in 
26 consecutive patients that underwent restrictive surgery, with a follow-up of two years.  
 
Results 
During the first six months after bariatric surgery, sE-selectin levels decreased. Despite substantial 
weight loss, sICAM-1 and sVCAM-1 plasma levels did not decrease significantly. After 24 months, 
sICAM-1 levels were significantly decreased while sE-selectin levels were further decreased. 
However, sVCAM-1 levels remained elevated. Adiponectin levels did not change significantly 
during the first six months after bariatric surgery, whereas resistin levels increased. After 24 
months, adiponectin levels were similar to normal weight controls, but resistin levels remained high.  
 
Conclusion 
Reductions in plasma levels of different markers of endothelial activation after bariatric surgery 
show different temporal patterns, suggesting that distinct mechanisms are involved in their 
regulation. Although not all endothelial activation markers normalize after bariatric surgery, our 
findings suggest that bariatric surgery can reduce endothelial activation on the long term. 
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Introduction 
Inflammation of the vascular wall is a crucial step in the pathophysiology of 
atherosclerosis which causes endothelial cells to express a wide variety of 
endothelial adhesion molecules, including Endothelial selectin (E-selectin), 
Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intercellular Adhesion 
Molecule-1 (ICAM-1). In order to limit the inflammatory process, these 
adhesion molecules are rapidly removed from the cell surface, which occurs by 
proteolytic cleavage and shedding1,2. The elevated circulating levels of 
products of proteolytic cleavage and shedding of adhesion molecules correlate 
with atherosclerosis1. Furthermore, plasma levels of soluble forms of ICAM-1 
(sICAM-1), VCAM-1 (sVCAM-1) and E-selectin (sE-selectin) are increased in 
obesity3,4.  
Recently, two proteins, adiponectine and resistin, which could affect expression 
of endothelial activation markers by endothelial cells, were discovered. 
Adiponectin and resistin have opposite actions on endothelial cells and plasma 
levels are respectively decreased and increased in human obesity5,6. The 
adipokine adiponectin downregulates expression of ICAM-1, E-selectin and 
VCAM-1, while resistin, which in humans is secreted by inflammatory cells7, 
upregulates these adhesion molecules8,9.  
Weight loss in obese and morbid obese individuals results in improvement of 
endothelial function10 and decreased circulating inflammatory markers11,12. This 
study was conducted to analyze the effects of weight loss after bariatric surgery 
on the levels of endothelial activation markers and their key regulators. 
Together with circulating plasma markers of endothelial activation (sICAM-1, 
sE-selectin and sVCAM-1), plasma levels of mediators of endothelial activation 
(adiponectin and resistin) were studied in a follow-up of 24 months, reflecting 
the degree of endothelial cell activation during weight loss after bariatric 
surgery. 
Subjects and methods 
Subjects and samples 
All participants gave written informed consent. The study was approved by the 
local ethical committee of the Academic Hospital Maastricht. 
A total of 26 consecutive subjects, admitted to the Surgical Department of the 
University Hospital Maastricht to undergo an operation for morbid obesity, were 
included in the study. The group comprised 23 female and three male 
individuals, aged 38±9 years with a mean BMI of 46.3±6.0 kg/m2. These 
patients underwent a primary operation for morbid obesity (Vertical banded 
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gastroplasty (VBG, n=12) or laparoscopic gastric banding using Lap-Band 
(n=14)). All subjects were selected to be otherwise healthy according to history, 
clinical examination and whenever possible laboratory findings, which means 
that no overt signs of type 2 diabetes mellitus, hypertension (diastolic blood 
pressure: 82.12±8.82 mmHg) and other cardiovascular diseases were present. 
Moreover, the individuals did not use any medications apart from oral 
anticonceptives.  
ten healthy lean subjects (eight female and two male) aged 35±14 years, with a 
mean BMI of 22.5±3.5 served as control group to provide reference values 
(values depicted as dotted lines in Figure 5.1.).  
Blood samples were collected after at least eight hours fasting using evacuated 
blood collection tubes containing EDTA one day before surgery, and 3, 6, 12 
and 24 months after surgery and processed as previously described11. 
Immunoassays 
Plasma concentrations of sICAM-1 and sE-selectin were determined using 
sandwich ELISAs as described elsewhere11,13. Plasma sVCAM-1, adiponectin 
and resistin concentrations were measured using ELISA development kits 
(R&D systems, Minneapolis, MN). All plasma samples were analyzed in the 
same run. The intra- and inter-assay coefficients of variance of the various 
assays were <10%. 
Statistical analysis  
All data are expressed as mean ± SD. Due to the non-parametrically distributed 
data, preoperative and postoperative results were compared using repeated 
measurements ANOVA (analysis of variance). A p-value less than 0.05 was 
considered statistically significant. 
Results 
Weight loss after surgery 
Restrictive bariatric surgery resulted in a significant loss of BMI from 
46.3±6.0 kg/m2 to 34.7±6.6 kg/m2 (p<0.01) during the two year follow-up 
period, which was not influenced by the restrictive bariatric surgical techniques 
used (Figure 5.1). During the first six months, a striking decrease in BMI and 
%EWL was observed, amounting to a remarkable mean 142 grams body 
weight loss per day, which decreased to a mean weight loss of 53 grams per 
day (6-12 months). Patients reached a stable weight after one year. 
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Figure 5.1 BMI of 26 morbidly obese subjects was determined preoperatively as well as after 
gastric restrictive surgery. BMI decreased after gastric restrictive surgery. Effect of 
weight loss due to gastric restrictive surgery on plasma levels of endothelial activation 
markers sICAM-1, sVCAM-1, sE-selectin, and their regulators adiponectin and resistin 
in 26 morbidly obese subjects. During the first months after bariatric surgery, 
adiponectin concentrations did not increase significantly whereas resistin levels did 
increase. After 12 months, adiponectin levels were significantly increased while 
resistin levels dropped to preoperative values. In contrast to plasma sE-selectin levels, 
sICAM-1 and sVCAM-1 plasma levels were still elevated during the first months after 
bariatric surgery. In the long term sE-selectin levels further declined and sICAM-1 
levels decreased significantly but sVCAM-1 concentrations remained elevated. The 
dotted line represents control values. Mean values and standard deviations are for 
sICAM-1 133.2+22.7 ng/ml, for adiponectine 8.27+4.6 µg/ml, for sVCAM-1 
354.6+108.2 ng/ml, for resistin 9.15+2.2 ng/ml and for sE-selectin 11.35+4.7 ng/ml. 
 * Significantly changed compared to preoperative values. 
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Effect of weight loss on endothelial activation markers 
Previously, we reported that inflammatory markers such as the acute phase 
protein lipopolysaccharide binding protein (LBP), CRP, and soluble TNFα 
receptors did not decrease during the first six months after bariatric surgery, 
even though the individuals lose substantial amounts of weight11. In line with 
this, circulating levels of the adhesion molecules sICAM-1 and sVCAM-1 
remained elevated (Figure 5.1). In contrast, plasma levels of sE-selectin rapidly 
declined during the first six months (Figure 5.1).  
In the long term (12-24 months) after bariatric surgery, levels of circulating 
inflammatory markers decreased11. Likewise, plasma sICAM-1 and sE-selectin 
levels further decreased to levels comparable to those measured in healthy 
controls (from 165.8±32.4 to 136.8±30.7 ng/ml (p<0.05) and from 23.8±9.5 to 
15.4±7.3 ng/ml (p<0.05), respectively). sVCAM-1 levels showed a trend to 
decrease from 1039.1±290.2 to 753.0±311.4 ng/ml, but remained elevated as 
compared to healthy controls. The decrease of endothelial activation markers 
did not correlate with the decrease in weight after bariatric surgery.  
Effect of weight loss on regulators of endothelial activation 
Despite substantial weight loss directly after bariatric surgery, only minimal 
changes in plasma adiponectin and resistin levels were seen. In the stable 
weight phase, after 12 months, adiponectin plasma levels had increased 
significantly from 6.4±3.6 to 7.6±3.0 μg/ml (p<0.05) (Figure 5.1). After 24 
months, however, adiponectin levels did not differ significantly from 
preoperative levels. Plasma resistin levels increased significantly during the 
period of substantial weight loss, from 17.7±7.5 to 22.1±7.3 ng/ml after six 
months (p<0.05), but decreased to preoperative values once stable weight was 
achieved (Figure 5.1). 
Discussion 
Cardiovascular diseases are common in morbid obese individuals. Endothelial 
cell activation is thought to play a causative role in the development of 
cardiovascular diseases. In this study we have monitored levels of endothelial 
cell activation markers and their main regulators in morbid obese individuals up 
to two years after bariatric surgery. During the first six months after bariatric 
surgery, plasma sICAM-1 and sVCAM-1 concentrations remained high. In 
contrast, sE-selectin, decreased significantly during this period. This suggests 
that endothelial cells remain in an activated state during this period, although 
the effects of weight loss are already reflected in components of the endothelial 
activation state. Since plasma adiponectin levels did not change and resistin 
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levels even increased during the first months after bariatric surgery, it is 
unlikely that these mediators of endothelial activation in vitro are responsible 
for the partial reduction of endothelial cell activation. Instead, inflammatory 
mediators may be responsible for this effect. In a previous report, we 
hypothesized that a severe catabolic state, brought about by substantial weight 
loss, could be responsible for metabolic stress, resulting in an ongoing 
inflammatory state during the first months after bariatric surgery11. This may 
explain why the reduction in endothelial cell activation is initially only minor. In 
this respect it is also noteworthy that, similar to the endothelial activation 
markers, there are marked differences with respect to the degree of 
normalization of inflammatory mediators during the first months after surgery. 
PAI-1 and the acute phase protein α1-acid glycoprotein (AGP) levels, like sE-
selectin levels, decrease rapidly, whereas sICAM-1 and sVCAM-1 levels, like 
LBP and CRP levels, remain elevated. These findings suggest that there is no 
uniform mechanism by which weight loss leads to decreased endothelial 
activation and inflammation, although parallel mechanisms may operate in both 
processes.  
Once weight stabilization was reached (approximately 12-24 months 
postoperatively) the inflammatory condition diminished. In line with this, we 
report substantially decreased levels of the endothelial activation markers 
sICAM-1 and sE-selectin as well as increased plasma adiponectin 
concentrations 12-24 months after operation. On the other hand, resistin and 
sVCAM-1 levels remained elevated. A possible explanation can be that the 
subjects in our study were still obese, even at 24 months after gastric restrictive 
surgery (mean BMI of 34.7 kg/m2). It has been shown that obese individuals 
have elevated resistin levels14, which can explain the high levels of resistin 2 
years after surgery.  Analogous to this, sVCAM-1 levels in obese subjects are 
higher than those in normal weight controls, as also shown by Vazquez et al.15. 
 
Although almost exclusively secreted by adipocytes, adiponectin levels in 
obese individuals are lower than levels in normal weight control subjects and 
increase after weight loss16. The low-grade inflammatory state associated with 
obesity is thought to be responsible for the decreased adiponectin production17. 
Therefore, the ongoing inflammation during the first months after bariatric 
surgery may suppress an increase in adiponectin levels, despite substantial 
weight loss. After stable weight is achieved, the low-grade inflammation 
attenuates and adiponectin levels increase accordingly. 
Resistin upregulates endothelial activation markers via a NF-κB or AP-1 
dependent pathway9. Adiponectin downregulates the expression of adhesion 
molecules through cAMP dependent inhibition of NF-κB signaling8. Moreover, 
endothelial activation markers have been reported to be upregulated by pro-
78⏐Chapter 5 
inflammatory cytokines13. This can explain the prolonged increase of sICAM-1 
and sVCAM-1, but not the rapid decrease of sE-selectin during the first months 
after bariatric surgery. One possible explanation for the observed discrepancy 
is the source of the different activation markers. sICAM-1 is not exclusively 
secreted by endothelial cells. The observed increased plasma concentrations 
of resistin could imply that monocytes are activated during the first few months 
after bariatric surgery. Monocytes are also capable of producing sICAM-118, 
which could explain the prolonged increased plasma levels of sICAM-1 after 
bariatric surgery. Another possibility for the observed discrepancy could be the 
observation that sE-selectin plasma levels are more sensitive than sVCAM-1 
and sICAM-1 plasma levels for the hyperinsulinemic state in individuals with 
impaired glucose tolerance19. Directly after bariatric surgery insulin levels 
rapidly decrease20 which might explain the rapid decrease of sE-selectin levels 
during the first months after bariatric surgery, while sICAM-1 and sVCAM-1 
plasma levels are still increased.  
In summary, levels of endothelial activation markers diminish after bariatric 
surgery induced weight loss, leading to a decreased pro-atherogenic state. 
This underscores the importance of bariatric surgery in reducing major co-
morbidities of morbid obesity, like cardiovascular disease.  
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Abstract 
Background 
Recent studies show that morbid obesity is associated with activation of the innate immune 
response. Neutrophil activation is a fundamental process in the innate immune response. 
Therefore, the activation state of neutrophils in morbidly obese subjects and the effect of bariatric 
surgery on neutrophil activation was evaluated.  
 
Methods 
Neutrophil activation was assessed by measuring circulating concentrations of myeloperoxidase 
(MPO) and calprotectin in 37 morbidly obese and nine control subjects (ELISA). Moreover, 
membrane expression of CD66b on circulating neutrophils was measured using flow cytometry in a 
group of seven morbidly obese and six control subjects. Immunohistochemical detection of MPO 
was performed in adipose and muscle tissue.  
 
Results 
Plasma MPO and calprotectin levels were significantly increased in morbidly obese subjects as 
compared to healthy controls, 27.1±10.8 vs. 17.3±5.5 ng/ml (p<0.001) and 115.5±43.5 vs. 
65.1±23.1 ng/ml (p<0.001) for MPO and calprotectin respectively. In line, CD66b expression was 
significantly increased in morbidly obese individuals, 177.3±43.7 vs. 129.7±9.2 (mean fluorescence 
intensity) (p<0.01). Bariatric surgery resulted in decreased calprotectin, but not MPO plasma levels. 
Adipose and muscle tissue did not contain enhanced numbers of MPO expressing cells in morbidly 
obese individuals. 
 
Discussion 
These results point out that enhanced numbers of activated neutrophils are circulating in morbidly 
obese subjects. The reported data support the finding that the innate immune system is activated in 
morbidly obese individuals. Moreover, since neutrophils have a short lifespan, this indicates that 
the chronic inflammatory condition associated with morbid obesity is characterized by a continuous 
activation of the innate immune system. 
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Introduction 
The inflammatory condition associated with obesity is considered to play a 
major role in the pathogenesis of obesity-related morbidities like cardiovascular 
disease and type 2 diabetes mellitus1. Several inflammatory molecules have 
been shown to be involved. For instance, tumor necrosis factor alpha (TNF-α) 
plasma levels are increased in morbidly obese patients2,3 and TNF-α knockout 
mice do not develop insulin resistance after diet induced obesity4. Moreover, 
selective upregulation of IκB kinase beta (IKK-β), an inducer of nuclear factor 
kappa B (NF-κB) in liver results in decreased insulin sensitivity5.  
So far most studies have focused on the role of macrophage activation and 
accumulation in adipose tissue, which has been shown to contribute 
significantly to insulin resistance6. However, it appears that there is a more 
general activation of the immune system. For instance, levels of acute phase 
proteins (C-reactive protein (CRP) and α1-acid glycoprotein (AGP)) are 
increased in morbid obesity and decreased after surgery-induced weight loss3. 
Moreover, circulating levels of endothelial activation markers are increased in 
obesity, indicating an activation of endothelial cells7. Furthermore, the 
complement system is activated in morbid obesity which decreases after 
weight loss8. Collectively, these findings indicate that the immune system is 
activated in obesity.  
Neutrophils represent one of the most prominent components of the innate 
immune system displaying strong phagocytic and anti-microbial activity. Their 
anti-microbial activity is mainly based on specific proteins stored in granules or 
in the cytoplasm, such as myeloperoxidase (MPO) and calprotectin. MPO is a 
potent enzyme stored in the azurophilic granules of neutrophils which is 
secreted upon neutrophil activation. MPO generates numerous reactive 
oxidants and radicals which cause oxidative damage to proteins, lipoproteins, 
lipids and DNA of target cells9. These characteristics of MPO are also important 
in the relation of MPO with cardiovascular disease. Zheng et al. showed that 
apolipoprotein A1 (ApoA1), the major lipoprotein of high density lipoprotein 
(HDL), is a specific target for MPO in atheroma, which could lead to plaque 
instability10. Moreover, the product of MPO controlled catalysis of hydrogen 
peroxide, hypochlorous acid, is thought to play a central role in the etiology of 
atherosclerosis11. Calprotectin is a cytoplasmic, bacteriostatic protein which is 
released upon activation12. Neutrophil activation is also accompanied by 
translocation of the glycoprotein CD66b from the secondary granules to the 
outer cell membrane and is involved in adhesion of neutrophils to E-selectin on 
the activated endothelium13. 
Earlier studies have shown that whereas the number of neutrophils remains 
unchanged in morbidly obese patients, expression of CD62L, an adhesion 
molecule on the neutrophil surface, was depressed14. Expression of other 
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activation markers by neutrophils, such as the Fc receptor CD16 and the 
adhesion molecule CD11b as well as plasma levels of the activation marker 
elastase were similar between obese patients and normal weight controls14,15. 
Therefore the current views are that neutrophils may be slightly less activated 
and not activated in the morbidly obese individual. However, other studies 
reported that the total number of circulating neutrophils was increased in obese 
individuals16,17. In addition, evidence for a role of MPO in the development of 
obesity in mice was recently reported. Overexpression of MPO in transgenic 
mice led to enhanced weight gain on a high fat diet18. Given these results and 
the notion that other components of the innate immune system are activated in 
morbidly obese subjects, we set out to evaluate the activation state of 
neutrophils in morbidly obese subjects. Here, it is reported that, in line with the 
activation of the innate immune response in morbid obesity, increased numbers 
of activated neutrophils are circulating in morbidly obese individuals. 
Subjects and methods 
Subjects and samples 
All participants gave written informed consent. The study was approved by the 
local ethical committee of the Academic Hospital Maastricht. 
To compare the neutrophil activation markers MPO and calprotectin between 
morbidly obese individuals and normal weight control subjects, a total of 37 
morbidly obese patients were compared to nine normal weight control subjects 
(study 1A). CD66b expression on neutrophils was studied in seven morbidly 
obese subjects and compared to CD66b expression on neutrophils of six 
normal weight controls (study 1B). The effect of bariatric surgery on neutrophil 
activation was studied in 15 consecutive subjects, admitted to the Department 
of Surgery of the University Hospital Maastricht to undergo an operation for 
morbid obesity (study 2). Characteristics of the different study groups are 
depicted in Table 6.1. All subjects were selected to be otherwise healthy 
according to history, clinical examination and whenever possible laboratory 
findings, which means that no overt signs of type 2 diabetes mellitus, 
hypertension, non alcoholic fatty liver disease and other cardiovascular 
diseases were present. Moreover, patients using anti-inflammatory medication 
like aspirin, statins and fibrates were excluded. 
For study 1A and 2, blood samples were collected after at least eight hours 
fasting using evacuated blood collection tubes containing EDTA and processed 
as previously described3. In study 1B whole blood samples were used. All 
samples were processed immediately for fluorescent activated cell sorting 
(FACS). 
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Immunoassays 
Plasma concentrations of MPO and calprotectin were determined using 
sandwich ELISAs (HyCult biotechnology, Uden, the Netherlands). All plasma 
samples were analyzed in the same run. The intra- and inter-assay coefficients 
of variance of the various assays were <10%. 
FACS analysis  
FACS analysis to detect CD66b expression on neutrophils was performed 
using the following protocol. 100 μl whole blood (EDTA) was incubated with a 
fluorescein-isothiocyanate (FITC) labeled antibody against CD66b. PBS and a 
FITC labeled isotype antibody were used as negative control. After 30 minutes 
of incubation in the dark, erythrocytes were lyzed and the vials were 
centrifuged at 400g. The supernatant was discarded and the cells were washed 
twice with PBS-0.1% BSA. Finally, cells were resuspended in 1% 
paraformaldehyde solution and FACS analysis was performed the same day on 
the FACSCalibur using Cellquest software (Becton Dickinson, Franklin lakes, 
NJ). Data are expressed as mean fluorescence intensity. 
Immunohistochemistry 
Slices of four micrometers of formalin fixed, paraffin embedded visceral 
adipose (omentum) and muscle (rectus abdominus) tissue were stained for 
neutrophil infiltration using an antibody directed against MPO. In short, slides 
were deparaffinized, rehydrated and incubated for 15 minutes in methanol-
0.6% H2O2 to block endogenous peroxidases. Thereafter, slides were 
incubated with 10% goat serum in TBS-0.1% BSA to prevent aspecific binding 
of the secondary antibody. After washing with TBS, slides were incubated with 
rabbit anti human MPO (1:1000). Goat anti rabbit IgG antibody labeled with 
HRP was used as a secondary antibody. AEC (3-Amino-9-ethylcarbazole) was 
used as substrate for peroxidase. Hematoxillin was used as a counterstaining.  
Reagents and materials 
Bovine serum albumin (BSA) was purchased from Sigma (St. Louis, MO). FITC 
labeled antibodies against CD66b (clone 80H3) and the isotype control were 
purchased from Serotec (Kidlington, England). Polyclonal rabbit anti human 
MPO was purchased from Dako (Glostrup, Denmark).  
Statistical analysis 
All data are expressed as mean ± SD. In study 1A and 1B, due to unpaired and 
non-parametrically distributed data, results were compared using the Mann-
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Whitney test. In study two, due to paired and non-parametrically distributed 
data, results were compared using the Wilcoxon sign rank test. A p-value less 
than 0.05 was considered statistically significant. 
Results 
Plasma markers of neutrophil activation are increased in morbid 
obesity 
Table 6.1 summarizes the patient characteristics of the morbidly obese and 
normal weight controls studied.  
 
Table 6.1 Characteristics of the study populations. 
Study  Group 1A Study Group  1B Study Group 2  
morbidly 
obese (n=37) 
controls 
(n=9) 
morbidly 
obese (n=7) 
controls 
(n=6) 
preoperative
(n=15) 
postoperative 
BMI (kg/m2)  46.0 ± 6.0  22.8 ± 3.0  43.8 ± 6.7  22.8 ± 2.6  46.0 ± 4.9 36.2 ± 7.4 
Age (yr)  37 ± 10  31 ± 11  47 ± 7  44 ± 12  36 ± 10  
Sex (male/female)  5 / 32  2 / 7  3 / 4  3 / 3  1 / 14  
Plasma MPO and calprotectin levels were compared between morbidly obese and normal weight 
controls in study 1A. In study 1B CD66b expression was studied and morbidly obese subjects were 
compared to normal weight controls. The effect of bariatric surgery on plasma MPO and 
calprotectin levels was studied in study 2. 
 
 
The plasma levels of the neutrophil activation markers MPO and calprotectin 
were measured in morbidly obese and normal weight controls (study group 
1A). Both circulating MPO and calprotectin levels were significantly increased 
in morbidly obese subjects as compared to healthy controls. The levels of MPO 
were 27.1±10.8 ng/ml in the morbidly obese group whereas normal weight 
controls showed plasma levels of 17.3±5.5 ng/ml (p<0.001). For calprotectin, 
plasma levels were 115.5±43.5 ng/ml in the morbidly obese group, whereas 
plasma levels of normal weight controls were 65.1±23.1 ng/ml (p<0.001) 
(Figure 6.1). 
CD66b expression on neutrophils is increased in morbidly obese 
individuals 
The activation marker of circulating neutrophils, CD66b, was assessed using 
flow cytometry. CD66b was measured in a smaller group of seven morbidly 
obese and six normal weight healthy controls (see for characteristics Table 6.1, 
study group 1B). Like MPO and calprotectin plasma levels, CD66b expression 
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was significantly increased in morbidly obese individuals, 177.3+43.7 vs. 
129.7+9.2 (p<0.01) (Figure 6.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Circulating MPO (A) and Calprotectin (B) levels in morbidly obese and normal weight 
subjects (study group 1A). The levels of MPO were 27.1+10.8 ng/ml in the morbidly 
obese group whereas normal weight controls showed plasma levels of 17.3+5.5 ng/ml 
(p<0.001). For calprotectin, plasma levels were 115.5+43.5 ng/ml in the morbidly 
obese group, whereas plasma levels of normal weight controls were 65.1+23.1 ng/ml 
(p<0.001)   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 CD66b expression on the neutrophil cell membrane quantified by mean fluorescence 
intensity  in morbidly obese and normal weight subjects (study group 1B). CD66b 
expression was significantly increased in morbidly obese individuals, 177.3+43.7 vs. 
129.7+9.2 (p<0.01). 
The effect of bariatric surgery on plasma markers of neutrophil 
activation (study group 2) 
Weight loss after bariatric surgery is associated with decreased plasma levels 
of inflammatory mediators. Interestingly, MPO levels remained unchanged after 
bariatric surgery (19.7±4.1 ng/ml preoperative and 21.5±6.8 ng/ml two years 
postoperative). On the other hand, two years after bariatric surgery, 
calprotectin levels decreased (eleven out of 15 patients) significantly from a 
Calprotectine
morbidly obese control
0
100
200
300
400
*
C
al
pr
ot
ec
tin
e
(n
g/
m
l)
MPO
morbidly obese control
0
20
40
60
80
*
M
P
O
 (n
g/
m
l)
C
al
pr
ot
ec
tin
e
(n
g/
m
l)
C
al
pr
ot
ec
tin
e
(n
g/
m
l)
M
P
O
 (n
g/
m
l)
M
P
O
 (n
g/
m
l)
CD66b
morbidly obese control
0
100
200
300
*
M
ea
n
flu
or
es
ce
nc
e
in
te
ns
ity
(a
rb
ita
ry
un
its
)
M
ea
n
flu
or
es
ce
nc
e
in
te
ns
ity
(a
rb
ita
ry
un
its
)
88⏐Chapter 6 
mean of 119.6±31.5 to a mean of 93.9±42.7 ng/ml (p<0.001). (Figure 6.3). The 
outliers of the calprotectin group were not identical with the outliers in the MPO 
group.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Effect of bariatric surgery on circulating plasma MPO and calprotectin levels. 
Preoperative and two year postoperative plasma levels of MPO and calprotectin were 
measured (study group 2).Two years after bariatric surgery, MPO levels remained 
unchanged after bariatric surgery (19.7±4.1 ng/ml preoperative and 21.5±6.8 ng/ml 2 
years postoperative). Interestingly, calprotectin levels decreased (11 out of 15 
patients) significantly from a mean of  119.6±31.5 to a mean of 93.9±42.7 ng/ml 
(p<0.001). 
Absence of neutrophils in adipose and muscle tissue  
To determine if the increased neutrophil activation is accompanied by 
enhanced neutrophil infiltration of adipose or muscle tissue, immuno-
histochemical staining for MPO was performed. From 17 morbidly obese 
subjects, subcutaneous and visceral adipose tissue as well as skeletal muscle 
was stained for polymorphonuclear cells. In seven of these patients, plasma 
levels of calprotectin and MPO were measured as part of study 1A and shown 
to be increased. MPO positive cells were detected solely in blood vessels of 
adipose tissue and skeletal muscle tissue. 
Discussion 
The inflammatory condition in morbidly obese subjects is characterized by 
activation of several components of the innate immune response. This is 
illustrated by increased plasma levels of acute phase proteins, endothelial cell 
activation markers, complement factors and cytokines derived from activated 
macrophages. Remarkably little is known about the activation of neutrophils, a 
central component in innate immunity, in obesity. Thus far available data 
suggests that neutrophils are less activated in morbid obesity14,15. This is in 
contrast to the overt evidence that the innate immune system is activated in 
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morbid obesity. Therefore, we set out to determine the degree of neutrophil 
activation using the plasma levels of calprotectin and MPO and neutrophil 
membrane expression of CD66b. MPO and calprotectin are primarily secreted 
by neutrophils although a minor secretion by activated monocytes cannot be 
excluded9,12,19. CD66b on the other hand is specifically expressed on the outer 
cell membrane of granulocytes and its expression is enhanced upon activation 
of the cells making CD66b a suitable marker for neutrophil activation. 
We show increased plasma levels of MPO and calprotectin in morbidly obese 
patients strongly indicating neutrophil activation. The observed increased 
neutrophil specific CD66b expression also strongly supports neutrophil 
activation in morbid obesity. A possible mechanism for the activation of 
neutrophils could be the increased plasma levels of leptin and TNF-α observed 
in morbid obesity. Leptin has been reported to activate neutrophils via indirect 
induction of TNF-α secretion by monocytes20. 
Our findings contrast with the study of Cottam et al., who reported a lower 
CD62L expression on neutrophils of morbidly obese individuals as compared to 
neutrophils of normal weight controls14. They concluded that neutrophils of 
morbidly obese patients are less capable of activation and migration to target 
tissues rendering such patients more susceptible to inflammatory diseases.  
In morbidly obese patients, enhanced numbers of macrophages have been 
reported in adipose tissue6. In this context, the relation of activation of 
neutrophils with neutrophil infiltration of adipose and muscle tissue was 
investigated. Positive staining for MPO containing neutrophils in both adipose 
and skeletal muscle tissue was confined to blood vessels, which was similar in 
both tissues, indicating that increased plasma MPO levels originate from other 
sources. 
Interestingly, MPO is associated with cardiovascular diseases, since elevated 
plasma MPO levels have been reported to predict the presence of coronary 
artery disease9. In addition, it has been shown that LDL receptor knockout mice 
overexpressing MPO, given a high fat diet, had increased aortic lesions and 
were more obese than their LDL receptor knockout littermates18. The latter was 
thought to result from effects of MPO on lipid metabolism.  
Interestingly both plasma MPO levels and obesity are considered independent 
risk factors for cardiovascular disease. Increased plasma levels of MPO as 
observed in the present study could therefore imply an additional risk for obese 
individuals for cardiovascular diseases. In another perspective, the causative 
role of MPO in cardiovascular disease and obesity provides opportunities for 
treatment options aimed at decreasing oxidative damage with anti-oxidants and 
related drugs21, a topic that needs further study. 
Bariatric surgery results in marked weight loss as well as decreased plasma 
levels of inflammatory mediators3,7. Therefore it was hypothesized that bariatric 
surgery would also result in decreased plasma levels of MPO and calprotectin. 
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The decreased plasma levels of calprotectin indeed indicate that neutrophils 
are less activated two years after bariatric surgery. Interestingly, similar to 
earlier observations that several parts of the inflammatory cascade do not 
decrease after substantial weight loss3,7, MPO levels remained elevated two 
years after bariatric surgery. The continuous obese status could explain these 
findings.  
In summary, we show that increased numbers of activated neutrophils are 
circulating in morbidly obese individuals. Bariatric surgery partly reduced 
neutrophil activation. These findings support the notion that morbid obesity is 
associated with activation of the innate immune response. Interestingly, the 
innate immune response is an acute inflammatory response, while obesity is 
considered a chronic inflammatory status. Therefore, obesity appears to be 
characterized by a chronic stimulation of the acute inflammatory response. 
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Abstract 
Background 
The low-grade inflammatory condition present in morbid obesity is thought to play a causative role 
in the pathophysiology of insulin resistance (IR). Bariatric surgery fails to improve this inflammatory 
condition during the first months after surgery, although on the long term surgery results in 
resolution of the inflammation. Considering the close relation between inflammation and IR, a study 
was conducted in which insulin sensitivity was measured during the first months after bariatric 
surgery. 
 
Methods 
Insulin sensitivity was measured using homeostasis model assessment insulin resistance (HOMA-
IR) and steady state plasma glucose (SSPG) levels in eleven subjects prior to surgery and when 
26% excess weight loss (EWL) (approximately two months after bariatric surgery) was reached. 
Moreover, plasma levels of leptin, acute phase proteins and TNF-α receptors were measured. 
 
Results 
SSPG levels after 26% EWL did not differ from SSPG levels before surgery (14.3±5.4 vs. 
14.4±2.7 mmol/l), whereas HOMA-IR values decreased significantly (3.59±1.99 vs. 2.09±1.02). In 
line with earlier studies plasma levels of inflammatory parameters did not improve, whereas leptin 
levels decreased. 
 
Conclusion 
During the first months after restrictive bariatric surgery a discrepancy was observed between 
HOMA-IR and SSPG levels. In contrast to SSPG levels HOMA-IR values showed improvement of 
insulin sensitivity. These results point out that HOMA-IR as surrogate marker of insulin sensitivity 
cannot be used during the first months after bariatric surgery. Moreover, the present data show that 
during the first months after restrictive bariatric surgery insulin sensitivity did not improve, leaving 
the patient at risk for the co-morbidities associated with IR. 
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Introduction 
Bariatric surgery is considered to be the best treatment option for morbid 
obesity and its co-morbidities1. In the long term bariatric surgery not only 
results in improved body weight but also reduces the low-grade inflammatory 
condition associated with morbid obesity2. The low-grade inflammatory 
condition is thought to play a causative role in the pathophysiology of insulin 
resistance. Supportive data for this hypothesis was generated in a study which 
showed that treatment of subjects suffering from insulin resistance with the 
anti-inflammatory drug acetylsalicylic acid resulted in improved insulin 
sensitivity3,4. In line, previous studies have shown increased insulin sensitivity 
and reduced inflammation in the long term after bariatric surgery5,6. 
Interestingly, prior data show, that despite substantial weight loss, several 
parameters of the low-grade inflammatory condition did not decrease during 
the first months after bariatric surgery5. Plasma adiponectin and resistin as well 
as acute phase proteins and tumor necrosis factor alpha (TNF-α) receptor 
levels remained unchanged at three months after surgery. This lead us to 
investigate insulin sensitivity of morbidly obese subjects before and at 
approximately two months after surgery when patients had lost 25% of excess 
weight in relation with inflammatory parameters. 
Materials and methods 
In total eleven consecutive patients admitted to the surgical department of the 
university hospital Maastricht for surgical treatment of morbid obesity, 
participated in the study. Seven patients underwent vertical banded 
gastroplasty (VBG) and four subjects a Lap-Band operation. In the study group, 
the subjects were otherwise healthy according to history, clinical examination 
and routine laboratory tests. In particular none of the studied subjects had 
evidence of diabetes mellitus or inflammatory disease or were taking 
medication known to influence glucose metabolism. The morbidly obese 
patients were studied with the SSPG test prior to gastric restrictive surgery 
(baseline) and after 25% excess weight loss (EWL). Characteristics of the 
study population are presented in Table 7.1. The study was approved by the 
ethical committee of the university hospital Maastricht, the Netherlands. All 
subjects gave written informed consent.  
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Table 7.1 Characteristics of the study population. 
Variables 
 
Preoperative 
(n=11) 
26% EWL 
(n=11) 
Sex (female/male)  9 / 2  
Age (yr)  40.4 ± 7.6  
BMI (kg/m2)  44.6 ± 3.3  39.4 ± 3.4* 
Waist hip ratio  0.97 ± 0.08  0.93 ± 0.1 
Weight loss (kg)   14.9 ± 3.3 
Fasting glucose (mmol/l)  5.4 ± 0.6  5.5 ± 0.7 
Fasting insulin (mU/l)  14.8 ± 7.8  7.4 ± 4.5* 
HOMA-IR   3.59 ± 1.99  2.09 + 1.02* 
Days after surgery   53 ± 26 
* p<0.05 compared to the preoperative situation. 
 
Steady State Plasma Glucose test 
Insulin sensitivity was determined by using SSPG levels, described by Reaven 
et al.7,8. This insulin suppression test determines a steady state plasma glucose 
(SSPG) concentration as a measure for insulin mediated glucose uptake and 
highly correlates (r>0.90) with the golden standard, the hyperinsulinemic 
euglycaemic clamp technique.  
In short after a 12-hours overnight fast, body weight and body height were 
measured. Subjects were studied supine in a hospital bed. Catheters were 
placed in both antecubital veins to enable infusion of glucose, insulin and 
octreotide as well as venous blood sampling. During an acclimatisation period 
of thirty minutes an automatic blood pressure measurement (Dinamap, Criticon 
Inc., Tampa, Fl) was performed. Octreotide (Sandostatin, kindly provided for by 
Novartis Pharma B.V. Arnhem, the Netherlands), a somatostatin analogue, was 
administered intravenously by using a syringe infusion pump (Treonic IP4, 
Vickers Medical, England) at 5.0 µg/min, preceded by a bolus of 25µg. Due to 
the expected severe insulin resistance in the study population a higher infusion 
rate was used than described by Pei and Reaven9. In both the pre- and 
postoperative measurements of SSPG the same octreotide concentration was 
used decreasing change of confounding the results due to high octreotide 
plasma concentrations. Insulin (Actrapid, Novo-Nordisk, Bagsærd, Denmark) 
was infused at a rate of 25 mU/m2/min by a second syringe pump. Glucose 
was infused via a volumetric pump (IVAC 591, IVAC Corporation, San Diego, 
CA) at 240 mU/m2/min. Before the test as well as on different time points during 
the test venous blood samples were taken. The mean plasma level of glucose 
at 150, 160, 170 and 180 minutes was defined as SSPG level. SSPG levels 
provide an indirect measure for insulin resistance. 
Plasma glucose was determined by a glucose oxidase method (YSI model 
2300 Stat, Yellow Springs Industries, Yellow Springs, OH). Blood samples for 
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determining inflammatory mediators and insulin were immediately put on 
melting ice and plasma was prepared by centrifugation at 1,400g for ten 
minutes at 4°C. The plasma was spun again at 2,700g for 10 minutes at 4°C 
and recovered plasma was stored in aliquots at -80°C until measurement. 
Reagents, materials and assays 
Plasma concentrations of soluble TNF-α receptors, leptin, lipopolysaccharid 
binding protein (LBP), C-reactive protein (CRP), α1-acid glycoprotein (AGP) 
and insulin were measured using sandwich ELISA’s. TNF-α receptors (55 and 
75), leptin, LBP, CRP and AGP were measured as described elsewhere5. 
Plasma insulin concentrations were measured using a commercial available 
ELISA (Mercodia AB, Uppsala, Sweden). 
All plasma samples were measured in the same run, except for plasma insulin 
concentrations. When plasma concentrations exceeded the upper detection 
limit of the assay, samples were additionally diluted and analyzed in a separate 
run with an overlap. The intra- and inter-assay coefficients of variance of the 
assays were smaller than 10%. 
Statistical analysis 
Data were expressed as mean ± standard deviation. The Wilcoxon sign-rank 
test was used to analyze differences. 
Results 
Effect of weight loss on metabolic and inflammatory mediators 
After bariatric surgery, 26±4% excess weight loss (EWL) was reached in 53±26 
days resulting in BMI loss from 43.9±3.6 kg/m2 (preoperative) to 
39.4±3.4 kg/m2.  
As shown in Table 7.1, fasting plasma glucose levels before surgery were in a 
normal range (<5.6 mmol/l), with increased fasting plasma insulin levels 
(14.8±7.8 mU/l) resulting in increased HOMA-IR (3.59±1.99). Fasting plasma 
glucose levels at 26% EWL were similar to preoperative values. In contrast, 
fasting insulin plasma levels as well as HOMA-IR decreased after surgery 
(7.4±4.5 mU/l and 2.09±1.02 respectively).  
Figure 7.1 shows pre- and postoperative steady state plasma insulin (SSPI) 
levels and SSPG. Because SSPI levels were not significantly different between 
the two conditions (p=0.76), pre- and postoperative SSPG levels could be 
compared. Preoperative glucose levels increased to reach the SSPG 
concentration (mean of plasma glucose levels from t=150 to t=180) of 
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14.4±2.7 mmol/l. This concentration is much higher compared to the SSPG 
levels found in healthy subjects (4.1±0.4 mmol/l), indicating reduced 
preoperative insulin sensitivity in our morbidly obese subjects. These data 
represent the lower 30th percentile of insulin resistance as measured by the 
group of Reaven in 490 healthy volunteers10. 
 
  A                                                            B 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Preoperative SSPI values (Figure 7.1A) did not significantly differ compared to 26% 
EWL (14.4±2.7 vs. 14.3±5.4 mmol/l), therefore pre and postoperative SSPG levels 
could be compared. SSPG levels did not decrease in the first months after restrictive 
bariatric surgery, indicating that during the first months after surgery insulin sensitivity 
did not improve. 
 
 
Interestingly, the mean SSPG concentration before surgery was not 
significantly different to the mean SSPG concentration after bariatric surgery at 
26% EWL (14.3±5.3 mmol/). 
In the long term after bariatric surgery SSPG levels improve substantially 
(8.2±3.2 mmol/l) according to data in a group of individuals three years after 
bariatric surgery11 (grey lines in Figure 7.1). However, compared to the 
preoperative and 25% EWL group, SSPI levels in the group three years after 
bariatric surgery were lower (43.6±10.0 vs. 28.7±9.8 mU/l). The preoperative 
BMI of this study population was 47.4±6.4 kg/m2, at approximately three years 
after bariatric surgery, patients had reached a BMI of 31.3±4.9 kg/m2 (70% 
EWL). Fasting plasma glucose and insulin levels were within the normal range 
(5.5±0.6 mmol/l and 4.5±2.9 mU/l respectively) resulting in normal HOMA-IR 
values (1.11±0.55).  
As reported earlier plasma leptin levels decreased significantly, whereas 
circulating levels of acute phase proteins (CRP, AGP and LBP) and TNF-α 
receptors did not change despite the substantial weight loss at timepoint 26% 
EWL5 (Table 7.2). 
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Table 7.2 Levels of inflammatory mediators at t=0 during the SSPG test of both study groups. 
Variables 
 
Preoperative 
(n=11) 
26% EWL 
(n=11) 
Leptin (ng/ml)  67.0 ± 31.5  26.9 ± 14.3 * 
CRP (μg/ml)  20.3 ± 12.1  21.9 ± 17.1 
AGP (ng/ml)  12.1 ± 7.7  10.3 ± 5.2 
LBP (μg/ml)  36.2 ± 16.9  35.1 ± 11.6 
Soluble TNFR55 (ng/ml)   0.6 ± 0.21  0.67 ± 0.2 
Soluble TNFR75 (ng/ml)  1.07 ± 0.43  1.34 ± 0.47 
* p<0.05 compared to the preoperative situation. Only plasma leptin levels decreased significantly 
after surgery, illustrating the ongoing inflammatory state in the first months after bariatric surgery. 
Discussion 
This study shows that in line with prior studies, the inflammatory condition did 
not improve during the first two months after bariatric surgery. A possible 
explanation could be metabolic stress induced by a severe catabolic state, 
brought about by substantial weight loss. This is supported by the observations 
that anorexia nervosa is also characterized by a low-grade inflammatory 
condition. Normalizing the catabolic state of patients suffering from anorexia 
nervosa by refeeding improves the inflammatory state12,13.  
Considering the close relation between inflammation and insulin resistance, 
insulin sensitivity was measured during the first months after surgery using 
SSPG levels. Interestingly, SSPG levels did not decrease two months after 
surgery,\ indicating that the patients still suffered from insulin resistance despite 
substantial weight loss. Although values could not be compared, due to 
significantly lower SSPI levels in the study group three year after surgery, data 
in the study group three years after bariatric surgery are strongly suggestive for 
improved SSPG levels in the long term after bariatric surgery. Low SSPI levels 
could lead to underestimation of the SSPG levels, which would imply that 
SSPG levels would decrease further with increasing SSPI levels. Further 
supporting the suggestion that insulin sensitivity improved in the long term after 
bariatric surgery are the HOMA-IR values, which are within the normal range. 
In contrast, HOMA-IR levels decreased significantly in the first months after 
surgery. This was mainly due to reduced fasting plasma insulin levels after 
surgery. Circulating fasting plasma glucose levels did not change significantly 
during the two months period. These results indicate that during the first 
months after bariatric surgery HOMA-IR should not be used as surrogate 
marker of insulin sensitivity. These findings also give rise to the hypothesis that 
observed differences between HOMA-IR and SSPG can be accounted for by 
the storage capacity of the liver for macronutrients. When losing weight rapidly 
hepatocytes will loose stored macronutrients earlier than skeletal muscle cells 
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or adipocytes, leading to increased insulin sensitivity of hepatocytes compared 
to skeletal muscle cells or adipocytes. Before surgery, liver gluconeogenesis 
results in increased insulin production. This leads in non type II diabetic 
morbidly obese patients, with insulin resistance, to increased fasting plasma 
insulin levels and normal or slightly increased fasting plasma glucose levels. 
We consider that directly after surgery, when the stored macronutrients content 
of the liver decreases rapidly, insulin sensitivity increases and gluconeogenesis 
decreases resulting in decreased fasting plasma insulin levels. 
A study using the euglycemic hyperinsulinemic clamp technique to measure 
insulin sensitivity has been performed after gastric bypass surgery and 
biliopancreatic diversion (BPD)14. Interestingly, six months after gastric bypass 
surgery insulin resistance did not decrease. In contrast, insulin resistance was 
significantly improved six months after BPD, which, as shown in another study, 
could be recovered within four weeks after BPD15. Taken together the present 
study and other data show that techniques mainly based on restriction, unlike 
malabsorptive procedures, do not immediately reduce peripheral insulin 
sensitivity. In general, gastric bypass surgery is considered restrictive, with only 
a minor malabsorptive component16. It is thought that incretins like glucagon 
like peptide-1 (GLP-1) and gastrointestinal polypeptide (GIP) play a central role 
in the observed differences15. Malabsorptive surgery results both in bypassing 
the foregut and in supplying the distal ileum with undigested food. 
Consequently secretion of GIP and GLP-1 is altered17. Both GIP and GLP-1 
are known to increase insulin sensitivity and secretion18 and therefore 
malabsorptive surgery is thought to be more effective in increasing insulin 
sensitivity than purely restrictive procedures.  
A possible explanation for the unchanged SSPG levels in the first months after 
bariatric surgery could be insufficient weight loss. At 26% EWL the subjects did 
loose approximately 15kg, but the BMI remained in the morbid obese spectrum 
(39.4 kg/m2). It is suggested that peripheral insulin sensitivity only starts to 
improve after a certain setpoint which has not been reached in the study 
population. Another explanation could imply the severe catabolic state 
associated with substantial weight loss in the first months after bariatric 
surgery. In line with this hypothesis are studies showing decreased insulin 
sensitivity in adipose tissue during fasting19, 20.  
In conclusion, these results show that, in line with the low-grade inflammatory 
condition, in the first months after restrictive bariatric surgery, despite 
substantial weight loss, insulin resistance does not improve. On the long term 
after bariatric surgery insulin sensitivity improved, emphasizing the role of 
bariatric surgery in the treatment of insulin resistance in morbidly obese 
patients. Interestingly, SSPG levels remained unchanged, while HOMA-IR 
decreased in the first months after bariatric surgery questioning the scientific 
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base for the use of HOMA-IR as a surrogate marker of insulin sensitivity during 
the first months after restrictive bariatric surgery. 
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Abstract 
Background 
Short time overfeeding of rats rapidly leads to insulin resistance (IR). A study with healthy human 
volunteers, which we suggest are less susceptible for developing IR after short time overfeeding, 
did not show these effects on IR. Therefore a study population of weight stable, formerly morbidly 
obese subjects (body mass index (BMI) 31.3 kg/m2), which were treated with bariatric surgery 
approximately three years ago was selected.  
 
Methods 
Eleven subjects were submitted to a seven days overfeeding study, resulting in a 53% increase in 
caloric intake (1227±394.4 to 1879.2±298.4 kCal/day). During normal diet and after overfeeding, 
insulin sensitivity was measured using steady state plasma glucose (SSPG) levels. At these time 
points, BMI and waist/hip ratio together with plasma levels of inflammatory markers (C-reactive 
protein (CRP), alpha-1 acid glycoprotein (AGP), lipopolysaccharide binding protein (LBP) and 
tumor necrosis factor alpha (TNF-α) receptors) and plasma leptin values were also measured. 
 
Results 
SSPG levels after overfeeding increased from 8.2±3.2 to 10.6±2.6 mmol/l (p<0.05), indicating 
decreased insulin sensitivity after overfeeding. Fasting plasma insulin, glucose, circulating levels of 
inflammatory markers as well as BMI and waist/hip ratio remained unchanged. 
 
Conclusion 
This study shows that overfeeding in a group of weight stable formerly morbidly obese subjects 
three years after bariatric surgery results in decreased insulin sensitivity. The mechanisms behind 
decreased insulin sensitivity induced by overfeeding are poorly understood, but the present results 
reveal that a unique human model is available to study these mechanisms, leading to a better 
understanding of the pathophysiology of IR. 
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Introduction 
The mechanisms that underlie insulin resistance in morbid obesity are in part 
unraveled. Increased fat mass and accumulation of fat in organs pivotal to 
glucose metabolism are thought to play a role. Moreover, the low-grade 
inflammatory condition associated with morbid obesity is also considered to be 
central to the pathophysiology of insulin resistance in morbid obesity1. 
Recently increased food intake accompanying morbid obesity is considered to 
be involved. Rats subjected to an overfeeding diet were shown to develop 
insulin resistance within seven days2. However, a study with human volunteers 
failed to show this effect of overfeeding on insulin sensitivity3. Selection of the 
study population could be the cause of the discrepancy between these studies. 
The population selected consisted of physically active healthy men with a mean 
BMI of 21.5 kg/m2. We considered that such normal weight subjects have 
sufficient buffer capacity to cope with increased food intake.  
Therefore, to investigate the effect of overfeeding on insulin sensitivity, a study 
population was selected consisting of former morbidly obese patients treated 
with bariatric surgery. These weight stable subjects are still mildly obese and 
had developed insulin resistance in the past, while being morbidly obese, which 
subsided after surgery4. 
Research design and methods 
Eleven consecutive subjects were included, two males and nine females. 
These subjects were on average 3.4 years after their surgical treatment for 
morbid obesity. Nine patients underwent vertical banded gastroplasty and two 
patients received a Lap-Band, both gastric restrictive procedures. At the 
moment of the experiment, all subjects had reached a stable body weigh for at 
least one year. The subjects were healthy according to history, clinical 
examination and routine laboratory tests. In particular none of the studied 
subjects had evidence of diabetes mellitus or inflammatory disease or were 
taking medication known to influence glucose metabolism. Characteristics of 
the study population are presented in Table 8.1. The study was approved by 
the ethical committee of the University Hospital Maastricht, the Netherlands. All 
subjects gave written informed consent.  
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Table 8.1 Characteristics and physiological parameters of the subjects during normal diet and 
after the overfeeding experiment. 
Variables 
 
Normal diet 
n=11 
After overfeeding 
n=11 
P-value 
Sex (female/male)  9 / 2   
Age (yr)  39 ± 18.5   
Weight (kg)  89.0 ± 18.9  89.8 ± 19.5 NS* 
BMI (kg/m2)  31.3 ± 4.9  31.5 ± 5.1 NS 
Waist/hip ratio  0.9 ± 0.1  0.9 ± 0.1 NS 
% EWL  70 ± 13.8   
Weight loss (kg)  47 ± 6.7   
Fasting glucose (mmol/l)  5.5 ± 0.6  5.5 ± 0.6 NS 
Fasting insulin (mU/l)  4.5 ± 2.9  4.7 ± 1.1 NS 
HOMA-IR  1.11 ± 0.55  1.14 ± 0.30 NS 
Days after surgery  1228 ± 394   
Energy intake (kcal/day)  1227 ± 394.4  1879.2 ± 298.4 p=0.005 
Carbohydrate intake (grams/day)  134.0 ± 32.3  214 ± 32.9 p=0.005 
Mean arterial pressure (mmHg)  92.5 ± 12.9  93.0 ± 9.9 NS 
* Not Significant 
 
Steady State Plasma Glucose (SSPG) measurement 
Insulin sensitivity was determined by using SSPG levels, described by Reaven 
et al.5,6This insulin suppression test determines a SSPG concentration as a 
measure for insulin mediated glucose uptake and highly correlates (r>0.90) 
with the golden standard, the hyperinsulinemic euglycaemic clamp technique.  
In short after a 12-hour overnight fast, body weight and body height were 
measured. Subjects were studied supine in a hospital bed. Catheters were 
placed in both antecubital veins to enable infusion of glucose, insulin and 
octreotide as well as venous blood sampling. During an acclimatisation period 
of thirty minutes an automatic blood pressure measurement (Dinamap, Criticon 
Inc., Tampa, Fl) was performed. Octreotide (Sandostatin, kindly provided by 
Novartis Pharma B.V. Arnhem, the Netherlands), a somatostatin analogue, was 
administered intravenously by using a syringe infusion pump (Treonic IP4, 
Vickers Medical, England) at 5.0 µg/min, preceded by a bolus of 25 µg. A 
higher infusion rate was used than described by Pei and Reaven7. In both the 
measurements during normal diet and measurements after overfeeding equal 
octreotide concentrations were used, decreasing the risk of confounding due to 
high octreotide plasma concentrations. Insulin (Actrapid, Novo-Nordisk, 
Bagsærd, Denmark) was infused at a rate of 25 mU/m2/min by a second 
syringe pump. Glucose was infused via a volumetric pump (IVAC 591, IVAC 
Corporation, San Diego, CA) at 240 mU/m2/min. Before the test as well as on 
different time points during the test venous blood samples were taken. The 
mean plasma level of glucose at 150, 160, 170 and 180 minutes was defined 
as SSPG level.  
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Plasma glucose was determined by a glucose oxidase method (YSI model 
2300 Stat, Yellow Springs Industries, Yellow Springs, OH). Blood samples for 
determining inflammatory mediators and insulin were immediately put on 
melting ice and plasma was prepared by centrifugation at 1,400g for ten 
minutes at 4°C. The plasma was spun again at 2,700g for ten minutes at 4°C 
and recovered plasma was stored in aliquots at -80°C until measurement. 
Study protocols 
All subjects were studied twice. Six subjects were studied while on their normal 
diet after gastric restrictive surgery and subsequently after one week of 
additional feeding. In the other five subjects the inverse sequence was used. 
To minimize the effects of the first SSPG test on the second, the mean interval 
between the two tests was 18 days (range 13-24 days). 
The feeding supplement consisted of three packets daily of 200ml liquid 
nourishment (Resource Energy Drink by Novartis Nutrition, the Netherlands), 
with a total energy content of 900kcal containing 113 gram carbohydrates and 
35 gram fat per day.  
In the week before the SSPG test, subjects were requested to keep a three day 
food-intake diary (registration was performed a one, three and five days before 
the test) to calculate total energy intake during additional feeding and during 
their habitual diet. Participant received detailed written and oral instructions on 
how to fill in the diaries. They were also asked to take the supplement between 
their usual meals in order to reduce satiety effects and to return all empty 
packets, in order to evaluate the amount of extra feeding consumed. The 
nutrient intake from food records were analyzed by using international food 
composition tables. 
Reagents, materials and assays 
Plasma concentrations of soluble TNF-α receptors, leptin, lipopolysaccharid 
binding protein (LBP), C-reactive protein (CRP), α1-acid glycoprotein (AGP) 
and insulin concentrations were measured using sandwich ELISA’s. TNF-α 
receptors (55 and 75), leptin, LBP, CRP and AGP were measured as described 
elsewhere8. Plasma insulin concentrations were measured using a 
commercially available ELISA (Mercodia AB, Uppsala, Sweden). 
All plasma samples were measured in the same run, except for plasma insulin 
concentrations. When plasma concentrations exceeded the upper detection 
limit of the assay, samples were additionally diluted and analyzed in a separate 
run with an overlap. The intra- and inter-assay coefficients of variance of the 
assays were smaller than 10%. 
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Statistical analysis 
Data were expressed as mean ± standard deviation. The Wilcoxon sign-rank 
test was used to analyse differences. A p-value of less than 0.05 was denoted 
as statistically significant. 
Results 
BMI and metabolic parameters of the study group  
The preoperative BMI of the study population was 47.4±6.4 kg/m2. At the time 
of the overfeeding experiment, at approximately three years after bariatric 
surgery, patients had reached a BMI of 31.3±4.9 kg/m2 (70% excess body 
weight loss (EWL)). Fasting plasma glucose and insulin levels were within the 
normal range and did not change after overfeeding. In the year before the 
overfeeding experiment the weight remained stable. Interestingly, the short 
period of overfeeding did not lead to a change in body weight or waist-hip ratio. 
Effect of additional feeding on insulin sensitivity in weight stable 
patients treated with restrictive bariatric surgery 
As shown in Table 8.1, overfeeding led to a 53% increase in daily calorie intake 
and a 59% increase in carbohydrate intake (both p=0.005). As assessed by 
food records, this additional feeding did not lead to changes in other dietary 
habits (food as well as liquid intake) in the period of extra food intake.  
Figure 8.1. shows steady state plasma insulin (SSPI) levels and SSPG levels 
during normal diet and after overfeeding. Because, SSPI levels were not 
different between the two conditions, SSPG levels could be compared during 
normal diet and after overfeeding. The mean SSPG concentration during 
normal diet was 8.2±3.2 mmol/l. SSPG concentrations were significantly higher 
following a period of overfeeding (10.6±2.6 mmol/l, p<0.05). These data clearly 
show that insulin sensitivity is reduced by high caloric intake. SSPG levels 
increased after overfeeding, both in the group subjected to measurements after 
overfeeding as well as in the group subjected to measurements before the 
overfeeding. This implies that the effect of overfeeding on insulin sensitivity is 
rapidly lost after a short washout period. 
Interestingly, HOMA-IR, a surrogate marker for insulin sensitivity, remained 
unchanged after overfeeding. 
Analysis of plasma levels of leptin and other inflammatory mediators revealed 
that overfeeding for seven days did not affect these parameters (Table 8.2).  
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Figure 8.1 SSPI and SSPG levels during the experiment. 
 Due to similar SSPI levels (Figure 8.1A), SSPG values of both conditions can be 
compared. During normal diet the SSPG values (figure 1b) are significantly lower 
(*:P<0.05) than after overfeeding (8.2±3.2 vs. 10.6±2.6 mmol/l), indicating that 
overfeeding results in decreased insulin sensitivity. 
 
 
Table 8.2 Levels of inflammatory mediators at t=0 during the SSPG test of both study groups. 
Variables 
 
Normal diet 
n=11 
After overfeeding 
n=11 
P-value 
Leptin (ng/ml)  15.7 ± 16.3  18.3 ± 17.6 NS* 
CRP (μg/ml)  2.3 ± 2.2  1.9 ± 1.3 NS 
AGP (ng/ml)  10.5 ± 8.1  8.5 ± 7.9 NS 
LBP (μg/ml)  12.7 ± 5.2  15.6 ± 4.4 NS 
Soluble TNFR55 (ng/ml)  0.72 ± 0.27  0.58 ± 0.21 NS 
Soluble TNFR75 (ng/ml)  1.26 ± 0.66  0.98 ± 0.66 NS 
* Not Significant. Despite decreased insulin sensitivity, inflammatory mediators remained 
unchanged. 
Discussion 
The influence of additional carbohydrate intake (total energy intake of 900 kcal 
per day) on insulin resistance using SSPG level measurement was assessed in 
weight stable patients, 1.5–4.5 years after gastric restrictive surgery. Insulin 
sensitivity decreased significantly after one week of additional feeding. The 
additional feeding led to a 59% increase in carbohydrate intake, without 
affecting fasting plasma glucose levels and circulating inflammatory mediators. 
In addition, no major changes in body weight were observed showing that 
increased caloric intake has a strong influence on insulin sensitivity in the 
population of morbidly obese subjects who have lost a significant amount of 
weight. These findings emphasize that bariatric surgery should not be 
considered a temporary intervention but should be implemented life long. A 
*
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similar study, which shows increased insulin resistance after a two week 
overfeeding regimen, has been performed in Pima Indians9. The interesting 
finding in our study is that, unlike the study in Pima Indians, insulin sensitivity is 
decreased without weight gain. This shifts the attention towards the effects of 
macronutrient intake on insulin sensitivity, and provides for an unique model to 
study the effects of macronutrient intake on insulin sensitivity, without the 
confounding effect of weight gain.  
Although SSPG levels showed that insulin sensitivity decreased, HOMA-IR 
failed to show this effect. In this respect our study also differs from the study in 
Pima Indians in which fasting insulin levels increased.  Unpublished data from 
our group revealed that this discrepancy between SSPG levels and HOMA-IR 
values also occurred during the first month after bariatric surgery, where SSPG 
data clearly shows that insulin sensitivity is not decreased, whereas HOMA-IR 
improved significantly. Metabolic stress either due to fasting or a caloric 
challenge is a common feature in both conditions, which raises the question if 
HOMA-IR as a surrogate marker for insulin sensitivity can be used during 
periods of metabolic stress. These findings also give rise to the hypothesis that 
observed differences between HOMA-IR and SSPG can be accounted for by 
the storage capacity of the liver for macronutrients. During the first stage of 
overfeeding macronutrients are stored in skeletal muscle and adipose tissue. 
As a result peripheral insulin sensitivity as measured by SSPG or hyper-
insulinemic euglycemic clamp techniques decreases. Skeletal muscle cells and 
adipocytes can still cope with the surplus of macronutrients in the first week of 
overfeeding and therefore the liver is relatively spared during the first week of 
massive overfeeding leading to normal fasting insulin and glucose plasma 
levels.  
Several mechanisms have been proposed to underlie insulin sensitivity in 
obese individuals. Currently, research mainly focuses on increased fat mass 
and accompanying changes in adipocytokine secretion and inflammation. 
Interestingly, induction of insulin resistance by overfeeding did not result in 
increased plasma levels of acute phase proteins and the TNF-α receptors 
showing that insulin sensitivity can decrease without overt changes in 
inflammatory parameters, normally closely correlated to insulin resistance. The 
results of the present study show that, in the absence of inflammation, 
increased nutrient intake (caloric challenge) could also play a role in the 
pathophysiology of obesity induced insulin resistance. One of the processes 
thought to play a major role in overfeeding induced insulin resistance is 
oxidative stress. Recently it was reported that a single glucose and fat 
challenge can induce oxidative stress in man10-12. In line, oxidative stress has 
recently been shown to be a causative factor in the pathophysiology of insulin 
resistance13.  
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Recently also ER-stress and the unfolded protein response have been linked to 
IR and obesity. Obesity is thought to increase the metabolic workload for cells 
resulting in accumulation of reactive oxygen species and intermediary 
metabolites, which activate the unfolded protein response14,15. Activation of the 
serine kinase c-Jun aminoterminal kinase (JNK1) induced by ER-stress 
suppresses insulin signaling16. Although it has been shown that obesity and 
oxidative stress can lead to ER stress no studies have shown a direct effect of 
overfeeding on ER stress, therefore studies are needed to unravel the role of 
ER stress in overfeeding induced insulin resistance. 
Plasma levels of the satiety hormone leptin also remained unchanged, whereas 
reported data shows increased levels of leptin after overfeeding2, 17. Leptin acts 
as an adipostat and although the study population substantially increases its 
caloric intake the total amount of calories is still below average 
(1879 kCal/day), which consequently does not lead to a rise in plasma leptin 
levels. 
Interestingly, the present study and the study in Pima indians9 shows 
decreased insulin sensitivity after overfeeding, while an overfeeding study in 
normal weight, physically active, healthy controls did not result in insulin 
resistance3. A reason for this difference could be the genetic background 
and/or metabolic alterations of the study population. For the present study 
former morbidly obese individuals in the stable weight phase after bariatric 
surgery were included. This population was known to suffer from insulin 
resistance before surgery, which was significantly improved at the time stable 
weight was achieved18. Compared to normal weight healthy controls this 
population could be metabolically altered, possibly under genetic control, 
during the process of becoming morbidly obese, resulting in an altered 
response to overfeeding. Moreover, this population is still obese and therefore 
has an increased risk of developing insulin resistance. In order to clarify the 
difference between the response to overfeeding in both groups, further studies 
are needed. 
In conclusion, the present study shows that increased food intake (caloric 
challenge) in the stable weight phase after bariatric surgery leads to decreased 
insulin sensitivity without weight gain. This implies that a unique human model 
is available to study mechanisms behind insulin resistance induced by 
overfeeding without the confounding effect of weight gain. 
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Mechanisms by which bariatric surgery increases insulin 
sensitivity 
Bariatric surgery has been shown to be an effective treatment option for morbid 
obesity and its co-morbidities, as insulin resistance1. Possible mechanisms by 
which bariatric surgery increases insulin sensitivity were reviewed in Chapter 2. 
The first part of this review discussed the theories regarding the effect of 
bariatric surgery on incretin secretion. As is generally recognized, bariatric 
malabsorptive surgery causes anatomical changes of the alimentary tract. 
These changes are thought to alter plasma incretin levels and consequently 
affect insulin secretion and action. Several authors describe a mechanism by 
which plasma incretin levels could alter after malabsorptive surgery. Increased 
amounts of unprocessed nutrients in the ileum could result in increased 
glucagon like protein-1 (GLP-1) plasma levels and increased insulin 
secretion2,3. The effect of bariatric surgery on guthormones can not solely 
explain the effect on insulin resistance. In literature bariatric surgery is also 
reported to lead to decreased nutrient intake causing reduction of fat mass and 
intracellular load of fat metabolites. In this context, from data described in the 
literature on the effect of these metabolic and behavioral changes induced by 
bariatric surgery, several mechanisms by which bariatric surgery could 
increase insulin sensitivity and inflammation were proposed.  
First, decreased nutrient intake is thought to lead to a reduced formation of 
reactive oxygen species (ROS), which are considered to be a causal factor in 
the pathophysiology of insulin resistance4. Moreover, it was suggested that 
reduced fat mass paralleling weight loss could result in alterations of circulating 
adipokine levels as well as less macrophage accumulation in adipose tissue. 
This and the proposed reduced formation of ROS might result in lower 
circulating levels of prodiabetogenic factors, like tumor necrosis factor alpha 
(TNF-α) and interleukin-6 (IL-6), as well as in enhanced plasma levels of the 
insulin sensitizing hormone adiponectin5. Finally, it was hypothesized that 
bariatric surgery could also result in enhanced β-cell functioning by reducing 
lipid accumulation in the pancreas. In addition, the decreased accumulation of 
lipids in myocytes and hepatocytes is reported to result in improved intracellular 
insulin signaling in these tissues6.  
Based on the review, the effect of bariatric surgery on the resolution of insulin 
resistance can best be explained by the anatomical changes leading to 
alterations in incretin levels and weight loss leading to decreased fat mass as 
well as intracellular lipid accumulation.  
118⏐Chapter 9 
Experimental and clinical studies 
The remaining chapters of this thesis concerned studies in morbidly obese 
patients which were treated or had been treated with bariatric surgery, applying 
different topics in bariatric surgery. With regard to weight loss, surgical 
techniques which bypass a part of the gastrointestinal tract for digestion are 
superior1.  
 
Next to malabsorption, postoperative plasma levels of satiety hormones may 
play a role in their effectiveness. Circulating levels of the orexigenic hormone 
ghreline are reported to decrease after gastric bypass surgery7. In Chapter 3, 
circulating levels of ghrelin and plasma levels of the satiety hormones leptin 
and insulin were evaluated after restrictive bariatric surgery in a two year 
follow-up study. Plasma ghrelin levels increased after vertical banded 
gastroplasty (VBG) or gastric banding surgery, whereas circulating insulin and 
leptin concentrations decreased. Gastric bypass was reported to result in lower 
plasma insulin and leptin levels and decreased plasma ghreline levels7,8. This 
led to the hypothesis, that differences in postoperative circulating ghrelin levels 
partly clarify the superior effect of gastric bypass surgery.  
 
The satiety hormone leptin was studied in Chapter 4 in the context of the 
immune system. From reported data on the immunoregulatory role of leptin, it 
was deduced that low circulating leptin concentrations might lead to abnormal 
responses of the immune system. Directly after bariatric surgery, morbidly 
obese patients are in a fasting state, suggestive for lower plasma leptin levels. 
Therefore, plasma levels of leptin during the first days after restrictive bariatric 
surgery were measured, presented and discussed. While even in morbidly 
obese patients leptin and body mass index (BMI) are closely correlated, 
circulating leptin levels strongly decreased in the first days after bariatric 
surgery, whereas the BMI did not change. Assuming that leptin has an 
immunoregulatory role it was hypothesized that such substantially decreased 
plasma leptin levels could explain the increased postoperative complication 
rate described after bariatric surgery.  
Further studies are necessary to elucidate this hypothesis. 
 
In the next chapters of this thesis, the inflammatory aspect of morbid obesity 
was studied. Recently, increased plasma levels of acute phase proteins (C-
reactive protein (CRP), alpha-1 acid glycoprotein (AGP) and lipopolysaccharide 
binding protein (LBP)) and cytokine receptors were reported in morbid obesity9. 
These observations imply activation of the innate immune response in morbid 
obesity. The low-grade inflammatory condition was further characterized in 
Chapters 5 and 6. 
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Circulating levels of endothelial activation markers as well as plasma levels of 
regulators of endothelial activation were subject of study in Chapter 5. 
Moreover, the effect of bariatric surgery on these inflammatory parameters was 
evaluated. Compared to healthy normal weight individuals, increased plasma 
levels of endothelial activation markers soluble endothelial selectin (sE-
selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble 
intercellular adhesion molecule-1 (sICAM-1) were found in morbidly obese 
patients. In addition, circulating resistin levels were increased, whereas 
adiponectin levels were decreased. Resistin is known to activate endothelial 
cells, while adiponectin is reported to down regulate endothelial activation10. 
These results show activation of endothelial cells in morbidly obese individuals. 
Bariatric surgery resulted in substantially decreased levels of the endothelial 
activation markers sICAM-1 and sE-selectin and increased plasma adiponectin 
at 12-24 months after surgery. Interestingly, resistin and sVCAM-1 levels 
remained elevated. A possible explanation for the latter observation may be the 
fact that the subjects in our study were still obese, even at 24 months after 
gastric restrictive surgery (mean BMI of 34.7 kg/m2).  
During the first six months after bariatric surgery, plasma sICAM-1 and 
sVCAM-1 concentrations remained unchanged, while sE-selectin levels 
decreased significantly. This suggests that endothelial cells remain activated, 
although the effects of weight loss are already reflected in sE-selectin levels. 
This is in line with previous reports, showing an ongoing inflammatory state 
during the first months after bariatric surgery, which was explained by 
metabolic stress caused by a severe catabolic state, brought about by 
substantial weight loss9. This assumption is supported by the observation that 
anorexia nervosa patients are also characterized by a low-grade inflammatory 
condition, which improves after refeeding these patients11. In this respect it is 
also noteworthy that, similar to the inflammatory markers studied in this thesis, 
there are marked differences with respect to the degree of normalization of 
inflammatory mediators during the first months after surgery reported in other 
studies. PAI-1 and AGP levels decrease rapidly, whereas LBP and CRP levels, 
remain elevated9. These findings suggest that there is no single mechanism by 
which weight loss leads to decreased endothelial activation and inflammation, 
although parallel mechanisms may operate in both processes. 
 
Neutrophils are also a major cellular component of the innate immune system. 
Therefore neutrophil activation in morbidly obese patients as well as the effect 
of bariatric surgery on circulating neutrophil activation markers was studied 
(Chapter 6). Plasma levels of the neutrophil activation markers myelo-
peroxidase (MPO) and calprotectin were measured preoperative and two years 
postoperative. MPO and calprotectin plasma levels were increased as 
compared to normal weight healthy controls. The increased levels of MPO and 
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calprotectin indicate neutrophil activation in morbidly obese patients. However, 
MPO and calprotectin production from monocytes could not be excluded. 
Monocytes have been shown to be activated in morbidly obese individuals and 
could therefore contribute to increased plasma levels of MPO and calprotectin. 
Therefore, the fraction of circulating neutrophils with enhanced CD66b 
expression, a specific marker of neutrophil activation, was compared between 
morbidly obese and normal weight control subjects12,13. Fluorescent flow-
cytometry revealed that CD66b expression of neutrophils was increased in 
morbid obesity.  
Decreased plasma levels of calprotectin were found two years after bariatric 
surgery, whereas circulating MPO levels remained unchanged. As mentioned 
before, the obese condition of these patients might explain the unchanged 
plasma levels some inflammatory parameters, like MPO, after bariatric surgery. 
The results from chapter 5 and 6 lead to the hypothesis that the low-grade 
inflammatory condition is characterized by activation of the innate immune 
response. Interestingly, the innate immune response is an acute response, 
whereas morbid obesity is a chronic disease. It is therefore concluded, that 
morbid obesity is associated with chronic stimulation of an acute inflammatory 
response. 
 
As mentioned previously, the low-grade inflammatory condition does not 
decrease during the first months after surgery, despite substantial weight loss. 
Inflammation has been reported to be causally related to insulin resistance an 
important co-morbidity associated with morbid obesity5. Therefore, insulin 
sensitivity as well as the inflammatory condition were evaluated in the first 
months after restrictive bariatric surgery (Chapter 7). At the time point that 25% 
EWL was reached, insulin sensitivity was not improved, as quantified with 
SSPG levels. In line, inflammatory parameters were not decreased at this time 
point. Paradoxically, HOMA-IR values, calculated using fasting insulin and 
glucose plasma levels, suggested increased insulin sensitivity. This study 
points out that in the first months after restrictive bariatric surgery, despite 
substantial weight loss, insulin resistance does not improve and levels of most 
inflammatory mediators remained high.  Interestingly, SSPG levels remained 
unchanged, while HOMA-IR decreased in the first months after bariatric 
surgery, questioning the scientific base for the use of HOMA-IR as a surrogate 
marker of insulin sensitivity during the first months after restrictive bariatric 
surgery. 
 
Next to inflammation and oxidative stress, increased food intake is also thought 
to play a role in the pathophysiology of obesity induced insulin resistance. The 
detrimental effects of increased food intake on insulin sensitivity was shown in 
rats, which were subjected to a seven day overfeeding period, resulting in 
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lower insulin sensitivity, a finding which is not supported by a human study14,15. 
The selection of study subjects in the latter study could be responsible for the 
discrepancy seen between both studies. Normal weight physical active healthy 
men were included in the human study. We considered that these subjects may 
have sufficient buffer capacity to cope with increased food intake. Therefore, a 
study population was selected with a history of high food intake and insulin 
resistance (Chapter 8). This population consisted of stable weight, mildly obese 
subjects who had lost weight from prior bariatric surgery (three years 
postoperatively). In this population a seven days overfeeding period resulted in 
decreased insulin sensitivity, showing that insulin resistance can be induced by 
overfeeding in specific groups. This implies that a unique human model is 
available to study mechanisms behind insulin resistance (IR) induced by 
overfeeding.  
Future directions 
In this thesis several hypothesis were tested, but more importantly studies 
presented in this thesis also generated new research questions. In this 
paragraph three questions are further discussed. The first question is how 
substantially decreased plasma leptin levels after bariatric surgery could 
explain the increased postoperative complication rate. A point of departure for 
future research might be the observation that leptin, produced by cells of the 
stomach, influence duodenal cholecystokinin (CCK) production as well as vagal 
afferent satiety signaling16. These findings broaden the perspective of leptin 
from a centrally acting satiety hormone to leptin as a peripheral paracrine 
hormone regulating satiety. Interestingly, oral administration of high fat nutrition 
is reported to inhibit inflammation in the splanchic area via increased CCK 
release, vagal CCK receptors and efferent vagal acetylcholine release, 
inhibiting activation of gut homing macrophages17. Hypothetically, also leptin 
could, via its receptors on the afferent vagal nerve, activate the efferent vagal 
nerve and inhibit macrophage activation. Therefore, the absence of food in the 
stomach after bariatric surgery and low circulating leptin levels could via CCK 
signaling lead to decreased inhibition of gut derived macrophages. This may 
possibly interfere with inflammatory processes needed for normal postoperative 
recovery of the bariatric patient, since these patients are thought to be more 
susceptible to develop postoperative complications18. 
 
From the data of Chapter 5 and 6 the hypothesis was deduced that morbid 
obesity is associated with a continuous stimulation of an acute inflammatory 
response. Due to reported data showing activation of leucocytes after 
macronutrient intake it is thought that continuous overfeeding, which 
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accompanies morbid obesity, could explain the chronic activation of the 
inflammatory response19. Future research should focus on this aspect. 
Measuring the activation state of circulating leucocytes using the overfeeding 
model described in Chapter 8 answers the question if this model also is 
suitable for studying overfeeding induced inflammation. However, according to 
Chapter 8 overfeeding for seven days does not lead to increased plasma levels 
of inflammatory proteins. Increasing the overfeeding period might provide 
information to explain this discrepancy. 
 
Finally, a research question which should be addressed in the future is to 
elucidate the mechanisms behind insulin resistance induced by overfeeding as 
described in Chapter 8. Future studies focusing on oxidative and 
endoplasmatic reticulum (ER) stress should be performed, using the model 
described in Chapter 8. The assumption that oxidative stress might be involved 
in the pathophysiology of insulin resistance is based on a number of studies 
reporting increased oxidative stress in circulating leucocytes20,21 following 
increased ingestion of macronutrients. In addition, reported data show that 
oxidative stress plays a causal role in the pathophysiology of insulin 
resistance4. Besides oxidative stress, ER stress has also been associated in 
literature with obesity and insulin resistance. Obesity is thought to increase the 
metabolic workload for cells, resulting in accumulation of reactive oxygen 
species and intermediary metabolites, which activate the unfolded protein 
response. Therefore, it is not surprising, that obesity is shown to be 
accompanied by increased ER stress, which is reported to increase serine 
phosphorylation of the insulin receptor substrate-1 resulting in insulin 
resistance22. 
Conclusion 
This thesis shows that morbid obesity is a systemic disease characterized by a 
low-grade inflammatory condition and co-morbidities like insulin resistance. 
Sustained resolution of the inflammation and co-morbidities can only be 
achieved by bariatric surgery, which should not be considered a temporary 
intervention but has to be implemented live long. 
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Samenvatting 
Gedurende de laatste decennia zijn de mensen in Nederland steeds dikker 
geworden. Zwaarlijvigheid (obesitas, Body Mass Index (BMI) >30 kg/m2) komt 
inmiddels bij 10,7% van de volwassen bevolking voor, terwijl er wordt geschat 
dat 1,5% van de volwassen bevolking ernstig zwaarlijvig (morbide obesitas, 
BMI >40 kg/m2) is. (Morbide) obesitas brengt veel problemen met zich mee, 
onder andere psychosociale- en gezondheidsproblemen. Vergeleken met een 
groep mensen die een normaal gewicht hebben, is bij obese mensen de kans 
om type 2 diabetes mellitus (ouderdomssuiker) te krijgen 5-20 maal verhoogd. 
Omdat type 2 diabetes mellitus een belangrijke risicofactor is voor het 
ontwikkelen van hart- en vaatziekten is het niet verwonderlijk dat het risico voor 
het ontwikkelen van hart- en vaatziekten bij obese mensen met een factor 4-6 
verhoogd is. Daarnaast is de kans om dikke darm- en borstkanker te 
ontwikkelen 4-6 maal hoger bij mensen met obesitas. De toename van 
obesitas gaat gepaard met een toename van het voorkomen van deze 
bijkomende ziekten, waardoor de kosten voor de gezondheidszorg stijgen. De 
directe en indirecte kosten worden geschat op respectievelijk 505 miljoen euro 
en 1,2 miljard euro per jaar1,2. 
Vanwege de grote belasting van (morbide) obesitas op de gezondheidszorg is 
het noodzakelijk goede therapeutische en preventieve interventies te 
ontwikkelen. Vanuit de literatuur is bekend dat op de lange termijn een 
combinatie van psychotherapie, dieet en fysiotherapie resulteert in een 
gewichtsverlies van maximaal 10%. Voor de obese populatie kan deze therapie 
afdoende zijn om naast de gewichtsproblematiek ook de bijkomende ziekten, 
zoals type 2 diabetes mellitus, te voorkomen. De meerderheid van de morbide 
obese populatie is echter onvoldoende gebaad bij deze maatregelen. De enige 
bewezen therapie voor de morbide obese patiënt is een operatieve techniek 
(bariatrische chirurgie). Om het gewenste effect te bereiken bestaan er grofweg 
twee verschillende vormen van bariatrische chirurgie. Restrictieve bariatrische 
chirurgie werkt voornamelijk door een verkleining van de oorspronkelijke 
maaginhoud. Voorbeelden van restrictieve chirurgie zijn de maagband, de 
vertical banded gastroplasty (VBG) en de gastric bypass operatie. Het andere 
operatietype is de malabsorptieve bariatrische chirurgie. Deze ingreep werkt 
doordat een deel van de darm wordt omgeleid, waardoor dit deel geen voedsel 
meer transporteert en dus ook geen voedingsstoffen kan opnemen. Zowel 
restrictieve als malabsorptieve technieken resulteren in aanzienlijk gewichts-
verlies. Bovendien wordt het voorkomen van bijkomende ziekten door 
bariatrische chirurgie drastisch verminderdt3-6. 
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Mechanismen waarmee bariatrische chirurgie de 
insuline-gevoeligheid verbetert 
In Hoofdstuk 2 zijn de mogelijke mechanismen verantwoordelijk voor het effect 
van bariatrische chirurgie op het verbeteren van de insuline-gevoeligheid 
beschreven. De positieve invloed van bariatrische chirurgie op plasma spiegels 
van incretines werd het eerst behandeld in dit overzichtsartikel. Incretines 
worden door de dunne darm gemaakt. Het zijn hormonen die de uitscheiding 
en werking van insuline positief beïnvloeden. Een voorbeeld hiervan is 
Glucagon Like Peptide-1 (GLP-1)7. Insuline is een belangrijk hormoon in de 
glucose stofwisseling. Ongevoeligheid van cellen voor insuline (insuline 
resistentie) kan suikerziekte veroorzaken. De productie van incretines door de 
darm kan beïnvloed worden door een deel van de dunne darm niet meer in 
contact te laten komen met voedsel. Biliopancreatische diversie (BPD) en 
gastric bypass chirurgie zijn voorbeelden van bariatrisch chirurgische operaties 
waarbij door een deel van de darm geen voedsel meer loopt. Na deze vormen 
van chirurgie stijgen de GLP-1 plasma concentraties. Dit kan worden verklaard 
doordat er onverteerd voedsel direct in de kronkeldarm terechtkomt. Hierdoor 
worden de zogenaamde L-cellen gestimuleerd om GLP-1 te produceren8. De 
rol van incretines in het postoperatieve herstel van de insuline-gevoeligheid is 
nog niet volledig uitgezocht en daarom zijn verdere studies op dit gebied nodig.  
Het positieve effect van incretines op de insuline-gevoeligheid na bariatrische 
chirurgie kan niet volledig het effect van bariatrische chirurgie op de insuline 
gevoeligheid verklaren. Bariatrische chirurgie heeft meerdere gevolgen. Ten 
eerste is de inname van voedsel verminderd waardoor de vetmassa afneemt 
en de intracellulaire stapeling van vetten verminderd. In dit overzichtsartikel 
werd aan de hand van literatuurgegevens beschreven wat de gevolgen van 
deze veranderingen zijn voor de insuline-gevoeligheid van een individu. 
Daarnaast gaat morbide obesitas gepaard met oxidatieve stress. Dit kan 
worden verklaard door de verhoogde inname van voedsel9,10. Een 
vermindering van de inname van voedingsstoffen zou in deze context tot een 
vermindering van oxidatieve stress kunnen leiden. Sinds kort wordt gedacht dat 
oxidatieve stress insuline resistentie kan veroorzaken11. Verminderde 
voedselinname door bariatrische chirurgie zal mogelijk de insuline-gevoeligheid 
kunnen verbeteren. Bovendien heeft bariatrische chirurgie ook tot gevolg dat 
de vetmassa verminderd. De verhoogde vetmassa bij obesitas gaat gepaard 
met een verandering in het uitscheidingspatroon van adipokinen (door 
vetcellen uitgescheiden stoffen) en een ophoping van macrofagen in het 
vetweefsel12. Enkele van deze adipokinen, zoals TNF-α en IL-6 verlagen de 
gevoeligheid voor insuline. Afname van de vetmassa zou dus de insuline-
gevoeligheid kunnen verhogen. Ten slotte gaat morbide obesitas gepaard met 
een verhoogde stapeling van vetten in lever- en spierweefsel wat de insuline-
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gevoeligheid verlaagd. Deze organen zijn belangrijk bij de glucose 
stofwisseling. Na bariatrische chirurgie vermindert de stapeling van 
metabolieten van vetzuren in deze organen, waardoor de insuline-gevoeligheid 
verbetert13.  
Experimentele en klinische studies 
In dit proefschrift zijn twee onderwerpen behandeld. De invloed van 
bariatrische chirurgie op verzadigingshormonen en het subklinische 
ontstekingsbeeld dat geassocieerd is met morbide obesitas en het effect van 
bariatrische chirurgie op dit ontstekingsbeeld.  
 
In Hoofdstuk 3 is nader ingegaan op de invloed van restrictieve bariatrische 
chirurgie op concentraties van verzadigingshormonen. Gastric bypass chirurgie 
leidt tot meer gewichtsverlies dan een maagband of VBG6. Er wordt mede 
verondersteld dat postoperatieve plasma concentraties van verzadigings-
hormonen een rol spelen bij het verschil in gewichtsverlies tussen VBG en 
gastric bypass. Na gastric bypass chirurgie dalen de plasma spiegels van de 
verzadigingshormonen ghreline, leptine en insuline. Het was nog niet bekend 
of dit ook plaats vindt na restrictieve bariatrische chirurgie. Daarom is er een 
studie uitgevoerd, waarbij plasma concentraties van de verzadigingshormonen 
ghreline, insuline en leptine voor en twee jaar na een maagband of VBG 
operatie zijn gemeten. Plasma ghreline spiegels stegen na de operatie. Dit in 
tegenstelling tot de in de literatuur beschreven gedaalde plasma concentraties 
na gastric bypass chirurgie14. Circulerende insuline en leptine concentraties 
daalden wel, zoals dat ook gerapporteerd is na gastric bypass chirurgie. 
Ghreline is een orexigeen hormoon, het leidt tot een stijging van de eetlust. 
Gestegen plasma ghreline spiegels na een maagband en VBG operatie 
zouden kunnen leiden tot een verhoogde eetlust en minder gewichtsverlies.  
 
Vanuit een andere invalshoek werd onderzoek gedaan naar het verzadigings-
hormoon leptine. Van dit hormoon is bekend dat het een immunoregulerende 
functie heeft, hetgeen nader wordt belicht in een overzichtsartikel in Hoofdstuk 
4. In de internationale literatuur wordt vermeld dat leptine deficiëntie ofwel door 
ontbreken van het leptine gen ofwel door langdurig vasten (anorexia nervosa) 
gepaard gaat met identieke afwijkingen van het immuunsysteem. Hierdoor 
wordt algemeen aangenomen dat te lage plasma leptine spiegels ongunstig 
zijn voor een individu. Kort na baratrische chirurgie zullen de patiënten niet tot 
nauwelijks eten. Doordat leptine een verzadigingshormoon is, werd er 
verondersteld dat de plasma leptine spiegels dalen tijdens de eerste 
postoperatieve dagen. Om dit te onderzoeken werd er een studie uitgevoerd 
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waarbij plasma leptine spiegels in de eerste dagen na de bariatrische ingreep 
zijn gemeten. Het resultaat was een sterke verlaging van plasma leptine 
spiegels gedurende de eerste dagen na bariatrische chirurgie. Waardoor de 
sterke samenhang tussen BMI en leptine spiegels die zelfs bij morbide obese 
patiënten nog aanwezig is verdwijnt. In deze periode is er sprake van een 
relatieve leptine deficiëntie omdat de concentratie van leptine in het plasma is 
hoger dan dat van een individu met een normaal gewicht. De sterk gedaalde 
leptine spiegels in de dagen na restrictieve bariatrische chirurgie zouden 
mogelijk het normale herstelproces na de ingreep kunnen verstoren. Verder 
onderzoek zal moeten uitwijzen wat de invloed is van postoperatieve leptine 
spiegels op het ontstaan en het beloop van complicaties na bariatrische 
chirurgie. 
 
In de volgende hoofdstukken werd het ontstekingsbeeld dat geassocieerd is 
met morbide obesitas behandeld. In eerdere studies is aangetoond dat 
morbide obesitas gepaard gaat met hogere plasma spiegels van acute fase 
eiwitten. eiwitten van het complement systeem en cytokines15,16. Dit leidt tot de 
aanname dat de aangeboren afweer is geactiveerd in morbide obesitas. In dit 
proefschrift werd dit verder uitgewerkt door activering van endotheelcellen en 
neutrofielen, de twee belangrijkste cellulaire componenten van de aangeboren 
afweer, te bestuderen.  
 
In Hoofdstuk 5 werd de mate van endotheelcel activering bepaald. Om dit te 
bepalen werd het plasma van morbide obese patiënten vergeleken met dat van 
gezonde controle personen met een normaal gewicht. In het plasma werden 
eiwitten gemeten die een maat zijn voor de mate van endotheelcel activering 
(sE-selectine, s-ICAM-1 en sVCAM-1). Daarnaast werden eiwitten gemeten die 
de endotheelcel activering reguleren (resistine en adiponectine). De 
bevindingen waren, dat in vergelijking met individuen met een normaal gewicht, 
plasma spiegels van sE-selectine, s-ICAM-1, sVCAM-1 hoger zijn bij morbide 
obese patiënten. Plasma resistine waarden zijn verhoogd, terwijl de 
circulerende adiponectine waarden verlaagd waren. Resistine verhoogt en 
adiponectine verlaagt de activeringsstatus van endotheelcellen. Samengevat 
geven deze resultaten aan dat endotheelcellen in de morbide obese patiënt 
meer geactiveerd zijn dan bij mensen met een normaal gewicht. In eerdere 
studies werd aangetoond dat de inflammatoire status afnam na bariatrische 
chirurgie15. Analoog aan die gegevens laten de data in dit proefschrift zien dat 
twee jaar na de operatie de plasma waarden van sE-selectine en sICAM-1 ook 
zijn gedaald en dat na een jaar de plasma adiponectine spiegels stijgen. 
Daarentegen zijn de sVCAM-1 en resistine spiegels in het plasma niet 
veranderd ten opzichte van de preoperatieve plasma spiegels. Een mogelijke 
verklaring is dat de patiënten nog steeds aanzienlijk obees zijn.  
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Alhoewel gewichtsverlies de inflammatoire status op de lange termijn doet 
afnemen, is dit op de korte termijn niet het geval. Dit is aangetoond in eerdere 
studies waarbij plasma spiegels van acute fase eiwitten en TNF-α receptoren 
niet daalden ondanks gewichtsverlies15. Adiponectine, resistine, sICAM-1 en 
sVCAM-1 plasma spiegels bleven gelijk of stegen ten opzichte van de 
preoperatieve plasma spiegels. Doordat de patiënten direct na de operatie veel 
minder kunnen eten, zal het lichaam de voedingsstoffen uit de eigen weefsels 
(vetweefsel, spierweefsel) moeten halen (katabolisme). Dit kan metabole stress 
veroorzaken en leiden tot het blijven bestaan van een ontstekingsbeeld 
ondanks aanmerkelijk gewichtsverlies. In lijn met deze aanname is de 
waarneming dat katabole anorexia nervosa patiënten ook een verhoogde 
inflammatoire status hebben, die vermindert als deze patiënten hervoed 
worden17. 
 
In Hoofdstuk 6 werd de activering van neutrofiele granulocyten in morbide 
obese patiënten besproken. Hiervoor zijn de neutrofiel eiwitten MPO en 
calprotectine gemeten in het plasma van morbide obese patiënten en een 
gezonde controle groep met een normaal gewicht. Plasma spiegels van MPO 
en calprotectine geven de mate van neutrofielactivering aan. Beide waren 
verhoogd bij morbide obese individuen, wat zou kunnen duiden op activering 
van neutrofielen in morbide obese patiënten. Omdat MPO en calprotectine niet 
alleen door geactiveerde neutrofielen worden geproduceerd, maar ook voor 
een klein gedeelte door geactiveerde monocyten, is het voorkomen van het 
eiwit CD66b op de celmembraan van de neutrofiel gemeten. De aanwezigheid 
van CD66b op de celmembraan neemt toe bij activering van neutrofielen, maar 
is niet aanwezig op monocyten18. In de studie werd bij morbide obese patiënten 
een verhoogde CD66b aanwezigheid op de celmembraan gevonden 
vergeleken met gezonde proefpersonen met een normaal gewicht. Deze 
bevindingen maken het aannemelijk dat de fractie geactiveerde circulerende 
neutrofielen hoger is bij morbide obese patiënten.  
Twee jaar na bariatrische chirurgie neemt de plasma calprotectine concentratie 
af. Dit geldt echter niet voor de MPO spiegels. De eerder genoemde verklaring 
dat bariatrische chirurgie weliswaar leidt tot aanmerkelijk gewichtsverlies, maar 
dat de patiënt nog steeds obees blijft, kan ook voor deze waarneming een 
verklaring zijn. 
 
Zoals eerder vermeld neemt het ontstekingsbeeld in de eerste maanden na 
bariatrische chirurgie niet af15. In de literatuur is beschreven dat er tussen 
ontstekingsstatus en insuline resistentie een sterk oorzakelijk verband 
bestaat19. Dit wordt ondersteund door studies met cellen waarbij TNF-α de 
insuline gevoeligheid van deze cellen doet afnemen20. Daarnaast wordt in een 
aantal studies, na behandeling met de ontstekingsremmer aspirine, een 
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verbetering van de insuline gevoeligheid beschreven21,22. Vanwege de sterke 
relatie tussen ontsteking en insuline resistentie en het blijvende ontstekings-
beeld in de eerste maanden na bariatrische chirurgie, werd de insuline 
gevoeligheid van patiënten in de eerste maanden na bariatrische chirurgie 
bestudeerd (Hoofdstuk 7). Hiertoe werd de insuline gevoeligheid gemeten voor 
de operatie en ongeveer twee maanden na de operatie bij 25% excess weight 
loss (EWL) door middel van Steady State Plasma Glucose (SSPG) 
concentraties en homeostasis model assessment - insulin resistance (HOMA-
IR). Het resultaat van de studie was dat op beide tijdstippen de insuline 
gevoeligheid, gemeten met SSPG concentraties, laag bleef. Als echter de 
HOMA-IR als indicator voor insuline gevoeligheid werd gebruikt, was de 
insuline gevoeligheid verbeterd bij 25% EWL. Dit geeft aan dat de patiënt na 
bariatrische chirurgie nog insuline resistent blijft en dat tijdens de eerste 
maanden na bariatrische chirurgie de HOMA-IR als surrogaat marker voor 
insuline gevoeligheid niet bruikbaar is.  
 
Zoals in deze discussie eerder werd vermeld spelen inflammatie en oxidatieve 
stress een belangrijke rol in het ontstaan van insuline resistentie. Oxidatieve 
stress kan worden geïnduceerd door een verhoogde inname van voedsel9,10 en 
leiden tot insuline resistentie. Bij studies in ratten is dit aangetoond, zeven 
dagen overvoeden leidt tot een verlaging van de insuline gevoeligheid23. In een 
studie bij mensen werd dit echter niet aangetoond24. In dit proefschrift wordt 
gesuggereerd, dat de selectie van proefpersonen voor deze studie een rol 
speelt in het niet kunnen veroorzaken van insuline resistentie door een 
verhoogde voedsel inname. Daarom is een populatie geselecteerd, waarvan 
verondersteld werd dat deze populatie genetisch en metabool gepredisponeerd 
is om insuline resistentie te ontwikkelen. Een groep proefpersonen werd 
geselecteerd die bestond uit mensen die 2-3 jaar na restrictieve bariatrische 
chirurgie een stabiel gewicht hadden bereikt, maar nog steeds obees zijn 
(Hoofdstuk 8). Het wordt algemeen aangenomen dat morbide obesitas gepaard 
gaat met een verminderde insuline gevoeligheid. De proefpersonen kregen per 
dag 650kCal extra boven op hun eigen dieet, hetgeen resulteerde in een 
verlaagde insuline gevoeligheid. Deze bevinding maakt duidelijk dat er een 
uniek humaan model beschikbaar is om de oorzaken achter overvoeding 
geïnduceerde insuline resistentie te onderzoeken.  
Toekomst 
Een mogelijk aanknopingspunt voor verder onderzoek is de waarneming dat 
CCK productie door het duodenum wordt beïnvloed door leptine, geproduceerd 
in de maag. Daarnaast wordt beschreven dat op de takken van de nervus 
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vagus die naar de hersenen lopen (afferente vagale zenuwbanen) leptine en 
CCK receptoren aanwezig zijn25. Vetrijke voeding zou de leptine productie in 
de maag kunnen verhogen. Het geproduceerde leptine kan de afferente vagale 
zenuwbanen activeren via de leptine receptor of via de CCK receptor. Het 
signaal gaat dan via de afferente vagale zenuwbanen naar de hersenen en 
weer terug via efferente vagale zenuwbanen naar de darmen. De activatie van 
de efferente vagale zenuwbaan zorgt ervoor dat er acetylcholine geproduceerd 
wordt door de zenuwuiteinden. Hierdoor wordt de activering van macrofagen in 
de darm geremd en de inflammatie in de darmwand onderdrukt26. Een lage 
plasma leptine spiegel of een lage leptine productie van de maag na 
bariatrische chirurgie heeft tot gevolg dat de remmende werking van het 
zenuwstelsel op macrofagen in de darm wegvalt. Hierdoor zou theoretisch de 
kans op postoperatieve complicaties groter worden. 
 
De bevindingen beschreven in de Hoofdstukken 5 en 6 laten zien dat morbide 
obesitas gepaard gaat met een activering van de aangeboren afweer. Het 
interessante is, dat de aangeboren afweer een acute ontstekingsrespons is, 
terwijl er bij obesitas sprake is van een chronisch ziektebeeld. Er werd daarom 
geconcludeerd dat morbide obesitas gekenmerkt wordt door een chronisch 
activering van een acute ontstekingsrespons. Verder onderzoek om dit uit te 
zoeken is nodig. 
Door in het model beschreven in Hoofdstuk 8 de inflammatoire veranderingen 
in circulerende leucocyten te meten, kan bestudeerd worden of dit model ook 
geschikt is om de invloed van overvoeden op inflammatie te onderzoeken. Er 
kan zich een probleem voordoen als de studieduur zeven dagen blijft omdat er, 
zoals in Hoofdstuk 8 is te lezen, in het plasma geen inflammatoire 
veranderingen te meten waren. Het verlengen van de overvoedingstijd zou dit 
probleem kunnen verhelpen. 
 
Uit Hoofdstuk 8 blijkt, dat het overvoeden van mensen kan leiden tot insuline 
resistentie. Dit leidt tot de vraagstelling welk mechanisme hiervoor 
verantwoordelijk is. In de toekomst zullen studies die zich richten op de rol van 
oxidatieve stress en endoplasmatisch reticulum (ER) stress een centrale rol 
moeten spleen om dit mechanisme op te helderen. De vooronderstelling dat 
oxidatieve stress een rol zou kunnen spelen in de pathofysiologie van insuline 
resistentie is onder andere gebaseerd op een aantal studies, waarin na het 
nemen van een verhoogde dosis macronutriënten de oxidatieve stress in 
circulerende leukocyten toeneemt9,10. Dat de rol van oxidatieve stress in de 
pathofysiologie van insuline resistentie een grote rol speelt wordt ook door 
studies in muizen bevestigd11. 
Naast oxidatieve stress, wordt ER stress ook geassocieerd met obesitas en 
insuline resistentie. Er wordt gesuggereerd dat de metabole belasting van een 
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cel bij obese personen is toegenomen, hetgeen resulteert in een verhoging van 
reactieve zuurstof radicalen en intermediare metabolieten. De ophoping van 
deze stoffen leidt tot de “unfolded protein response”. Hierdoor is het niet 
verwonderlijk dat obesitas gepaard gaat met ER stress, wat geassocieerd is 
met verhoogde serine phosphorylatie van de “insulin receptor substrate-1” 
hetgeen de cel minder gevoelig maakt voor insuline27. 
 
Samengevat kan worden gesteld dat uit resultaten van dit proefschrift blijkt dat 
morbide obesitas een systeemziekte is die onder andere wordt gekenmerkt 
door activatie van de aangeboren afweer. De systeemziekte morbide obesitas 
met de bijkomende inflammatie en aandoeningen kan alleen effectief 
behandeld worden met behulp van bariatrische chirurgie. Gezien het effect van 
overvoeding bij patiënten die bariatrische chirurgie hadden ondergaan, wordt 
duidelijk dat de anatomische veranderingen die deze ingreep met zich mee 
brengen geen tijdelijke oplossing zijn, maar levenslang van kracht moeten 
blijven. 
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Dankwoord 
Een proefschrift komt nooit alleen door de schrijver tot stand, daarom is een 
bedankje het minst wat ik kan doen. Hieronder vindt u dan ook een opsomming 
van mensen die, ieder op hun eigen manier, een bijdrage hebben geleverd 
tijdens het promotietraject. 
 
Allereerst zijn dat de proefpersonen. Zonder hun medewerking was dit alles 
niet tot stand gekomen.  
 
Vervolgens mijn beide promotoren Prof. dr. J.W.M. Greve en Prof. dr. W.A. 
Buurman. Voor beiden geldt dat ze, ondanks mijn eigenwijsheid, mij altijd zijn 
blijven stimuleren. Zonder hun standvastigheid was dit boekje niet tot stand 
gekomen. Daarnaast hebben ze mij de kans gegeven om het onderzoek te 
presenteren op verschillende binnen- en buitenlandse congressen.  
Beste Jan Willem, bedankt dat je mij, nu zes jaar geleden, de kans hebt 
gegeven om te promoveren. Je hebt het de afgelopen jaren, mede door je 
professoraat, steeds drukker gekregen. Desondanks heb je altijd tijd voor mij 
vrijgemaakt, bedankt hiervoor. We zullen elkaar in de toekomst zeker nog 
tegenkomen en ik hoop op een vruchtbare samenwerking. 
Beste Wim, de eerste ervaring die ik met je had was het sollicitatiegesprek. 
Natuurlijk was ik nog onervaren, maar ik dacht dat het na een half uurtje wel 
klaar zou zijn. Dat het bijna twee uur zou duren kon ik toen niet weten. Wat ik 
na die twee uur wist was dat ik een promotor zou krijgen met een zeer grote 
algemene ontwikkeling en onderbouwde mening over bijna alles. In totaal is het 
volgens mij 15 minuten over het onderzoek gegaan en de rest over politiek en 
andere interessante zaken. Ik ben het in ieder geval nog steeds met je eens 
dat een academicus verplicht (dagelijks) de krant moet lezen. Dat je altijd ter 
beschikking staat van je promovendi heb ik ervaren tijdens het schrijven van dit 
proefschrift. Elk tijdstip van de dag kon ik bij je terecht om dingen te bespreken, 
bedankt hiervoor.  
 
Dr. S.S.M. Rensen. Beste Sander, toen jij het obesitas onderzoek kwam 
versterken was ik langzaam de draad aan het kwijtraken. Projectje hier, proefje 
daar.. jij hebt daar weer lijn in gebracht. Ik heb de samenwerking altijd als zeer 
prettig ervaren en ik ben blij dat je mijn co-promotor wilt zijn. Je hebt vooral in 
het laatste deel van het voltooien van dit proefschrift veel werk verricht in de 
vorm van corrigeren, het submitten van manuscripten en het geven van 
praktische adviezen. Daarnaast moest je je vrouw (wen er maar aan) helpen 
met haar proefschrift en was je bezig met de voorbereidingen op je huwelijk. 
Voor mij is de samenwerking nog zeker niet beëindigd en ik hoop dat ik vanuit 
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de interne geneeskunde nog een goede bijdrage kan leveren aan het 
onderzoek. Veel succes de komende jaren. 
 
I would like to thank all members of the reviewing committee: Prof. dr. E.E. 
Blaak, Prof. dr. M.H. Hofker, Prof. dr. C.D.A. Stehouwer, Prof. dr. P.B. Soeters 
and dr. C.W. le Roux, for their evaluation of the manuscript. 
  
Zonder de studenten die mij hebben geholpen in de laatste jaren bij het 
verzamelen van de samples en het uitvoeren van kleuringen/ELISA’s was het 
zeker niet gelukt, bedankt voor jullie inzet. 
 
Mijn voorganger dr. F.M.H. van Dielen. Beste Francois, veel van de resultaten 
van dit proefschrift zijn afkomstig uit samples die jij hebt verzameld. Bedankt 
dat ik hiervan gebruik mocht maken. 
 
Yanti, ik ben blij dat je doorgaat met het werk dat nu is opgestart. Nu Sander jij 
en Gaukje zijn begonnen is er echt sprake van een obesitas team. Ik hoop na 
mijn promotie meer tijd te hebben om jullie vanuit de kliniek te ondersteunen. 
 
Rob, zonder jou is er geen bariatrische chirurgie meer denkbaar Jij bent de 
spin in het web en ik hoop dat we in de toekomst meer kunnen gaan 
samenwerken met het opzetten van een zorglijn. De chirurgen Sven van 
Helden en Nicole Bouvy wil ik ook bedanken voor hun hulp bij het verzamelen 
van de samples. Ruben, jij maakt het obesitas team compleet. Ik heb de 
samenwerking, ook al is die van korte duur geweest, altijd als zeer prettig 
ervaren. 
 
Mijn keuze om internist te worden is in gang gezet door gesprekken met Prof. 
dr. N.C. Schaper. Na de soms lange brainstormsessies over de SSPG 
metingen, kwam steevast de mededeling dat ik internist moest worden. 
Nicolaas, mijn keuze om me te blijven bezighouden met obesitas, zorgt er in 
ieder geval voor dat we nog veel met elkaar zullen samenwerken, ik verheug 
me hierop.  
 
Al mijn collega’s op het lab heelkunde, eerst op de 2e later op de 5e verdieping, 
wil ik bedanken voor de gezelligheid. Zo nu en dan een geintje op de afdeling 
zorgde voor de nodige ontspanning. Ik zie me nog door het ziekenhuis dwalen 
op zoek naar een pakketje dat zogenaamd voor mij afgeleverd was. Mo, Tim, 
Annemarie en Trudi, zonder jullie kennis en kunde op het gebied van ELISA’s, 
PCR, celkweken e.d. was mijn tijd een bij jullie een stuk moeilijker geweest. 
Mijn collega promovendi Marcel, Misha, Robert, Joep, Tim, Jacco, Geertje, 
Maarten, Martien, Maaike, Bart (2x), Bas en Yvonne; bedankt voor de leuke tijd 
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en kritische vragen. Ik wens een ieder van jullie veel succes in jullie verdere 
carrière. 
 
Kim en Evelien, bedankt voor de secretariële ondersteuning.  
 
Natuurlijk moet ik de wekelijkse voetbalavond niet vergeten. Allemaal 
competitief ingesteld, maar niet op het vervelende af, waardoor er bijna elke 
week een leuke pot gespeeld kon worden. Jammer dat het niet gecontinueerd 
kon worden, maar bedankt voor de leuke tijd. (van die beloofde borrel is niet 
veel meer terechtgekomen, maar ik hoop een deel van jullie wel op mijn feest 
te zien). 
 
Ik ben nu langzamerhand bij mijn huidige collega’s aanbeland. Maar voordat ik 
daar ben eerst een speciaal woord van dank voor twee personen die ik of hevig 
discussierend of in totale wanhoop achter een scherm zag zitten met net niet 
significante top-data. Steven en Martijn, het was altijd weer gezellig buurten bij 
jullie, hulde! 
 
Mijn collega’s op de interne geneeskunde, zowel stafleden, AIOS, verpleging 
en ondersteunend personeel ben ik dankbaar voor de prettige sfeer waarin de 
opleiding plaatsvindt. Ik hoop de volgende jaren nog met plezier met jullie 
samen te werken. 
 
Tiny, zonder jou expertise op het gebied van layout en planning was dit boekje 
er niet geweest. Dat je goed werkt levert blijkt wel uit de grote hoeveelheid 
boekjes die je al hebt afgeleverd. Bedankt! 
 
Zonder vrienden ben je nergens. Alleen als je tijdens je promotietraject 
kinderen krijgt en ook nog gaat verhuizen dan blijft er niet veel tijd meer voor 
jullie over. Pom, Edo (en Timo) en Annemiek, ondanks de moeite met plannen 
van de kookclubjes komen we toch regelmatig bij elkaar om de meest 
onmogelijke recepten uit te proberen. Ik hoop dit nog jaren te blijven doen.  
Jasper en Dorcas (en Éowyn), Mark en Esther (en Ben, Mirthe en Lieke), Mark 
en Marieke, Carine. De afgelopen jaren hebben we gewoon te weinig contact. 
Misschien en ik hoop het van harte gaat dit na de promotie verbeteren. 
 
De paranimfen Annemiek en Jasper, bedankt dat jullie tijd konden vrijmaken 
om naast mij bij te staan tijdens de verdediging. Ik wens jullie beiden veel 
succes met het voltooien van jullie onderzoek. 
 
De leden van opera comique Maastricht ook bedankt voor de leuke tijd en 
nodige ontspanning. Door de verbouwing en promotie heb ik de laatste tijd de 
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repetities iets laten versloffen, maar ik kom terug en in november zullen we een 
mooie productie neerzetten, daar ben ik van overtuigd. 
 
….. (vul hier je eigen naam in als ik je ben vergeten), heel erg bedankt voor de 
gezelligheid/hulp/mentale ondersteuning/samenwerking/vriendschap*.  
(* omcirkel wat van toepassing is) 
 
Beste Margreet, als moeder van Kirsten kan ik het mij voorstellen dat het vaak 
moeilijk is om te zien dat ik je dochter niet alle aandacht kan geven die ze 
verdiend. Daarnaast is het door de tijdsdruk vaak niet mogelijk om naar Zwolle 
af te reizen. Ik ben je dan ook heel erg dankbaar dat je, ondanks de drukte van 
jouw baan de tijd vindt om zo nu en dan naar het zuiden af te zakken om toch 
nog wat tijd met ons door te brengen.  
Thomas (en sinds kort Rachel), ik vindt het leuk voor je dat je, na al die jaren 
op een studeerkamer, een huisje hebt gevonden. Ik hoop dat je snel je draai 
vindt in Vlaardingen en daar een leuke baan vindt. Veel succes en plezier 
samen en tot ziens in jullie nieuwe huisje.  
 
Bas en Suzanne, ook voor jullie geldt dat jullie net samen een flatje hebben 
betrokken. Het is altijd leuk om te zien hoe je kleine broertje zich settelt en 
bezig is zijn eigen leven op te bouwen. Bas, ik ben trots op je dat je het voor 
elkaar hebt gekregen om een HBO studie af te ronden. Suzanne, we zullen 
elkaar als ik meer tijd heb wel beter leren kennen. 
 
Ronald en Yvonne (en Liam), de afgelopen tijd was ik er zeker te weinig voor 
jullie. Tijdens de onzekere tijd die jullie achter de rug hebben en die nog voor 
jullie ligt, zou ik er graag vaker voor jullie zijn. Nu de promotie achter de rug is 
hoop ik dat te kunnen doen. Los van alle perikelen van de afgelopen tijd is het 
de afgelopen jaren heel gezellig geweest, met als toppunt het totaal 
verregende weekje in Sorède.  
 
Pa en ma, zonder jullie was ik niet geweest wie ik nu ben. Bedankt dat jullie me 
in al mijn keuzes hebben gesteund. Ook jullie hebben moeilijke tijden gekend 
en alhoewel we veel contact hebben, had ik er in bepaalde situaties meer 
willen zijn. Een speciaal woord van dank voor jou pa, zonder jouw hulp was het 
kopen van ons nieuwe huis niet mogelijk geweest, zeker niet met de promotie 
en de geboorte van Aimée daarbij. Ma, dank je dat we pa zo nu en dan mogen 
lenen.  
 
Julian en Aimée, zonder jullie is het toch heel anders thuiskomen. Pappa is er 
de afgelopen tijd veel te weinig, het is zelfs zo erg dat zelfs zondag iemand 
anders het vlees snijdt. De komende tijd zal dat wel veranderen, maar pappa 
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heeft een vak gekozen waarbij hij niet altijd thuis kan zijn als jullie dat willen. 
Maar ondanks alles moeten jullie je bedenken dat pappa heel veel van jullie 
houdt. 
 
Kirsten, het is al meer dan vijftien jaar geleden dat wij wat met elkaar kregen. In 
die tijd waren we nog lang niet bezig met werktijden en dergelijke, maar als je 
toen geweten had wat je te wachten stond… Jij hebt gekozen voor een man 
die altijd bezig moet zijn. Het gevolg is dat ik het vrijwel altijd te druk heb. 
Alhoewel het tijdens mijn promotie beter is gegaan, realiseer je je maar al te 
goed dat er na de promotie weer andere uitdagingen wachten. Tot overmaat 
van ramp besloten we terwijl Aimée op het punt stond geboren te worden ons 
eerste huis te kopen. En niet zomaar een huis, nee eentje waar nog wat aan 
opgeknapt moest worden. Een relatie die een promotie doorstaat heeft zich al 
bewezen, maar eentje die én een verhuizing/verbouwing én een geboorte én 
een promotie doorstaat kan niet meer kapot. Ik beloof je, en nu staat het zwart 
op wit, dat ik de komende tijd meer aandacht ga besteden aan onze relatie. Dus 
collega’s, vrienden en familie als jullie er weer bij inschieten, ik heb een heel 
goede reden. 
 
Ik hef het glas op jullie gezondheid, 
 
 
Jeroen 
 
 
144⏐ 
 
  
 
 
 
 
 
Chapter 12 
 
 
 
 
 
 
Curriculum Vitae 
 
 
 
 
 
 
 
 
146⏐ 
 Curriculum Vitae⏐147 
Curriculum Vitae 
De schrijver van dit proefschrift is op 29 mei 1976 geboren in Enschede. In 
Veenendaal ging hij naar de middelbare school om vervolgens in Maastricht te 
beginnen met de studie milieugezondheidskunde. Na in 1996 het staats-
examen scheikunde te hebben behaald is hij begonnen met de studie 
geneeskunde aan de U niversiteit Maastricht. Tijdens deze studie heeft hij 
verscheidene functies als student-assistent gehad en fungeerde hij als penning- 
meester van het 3e Maastricht Medical Students Research Conference (MMSRC). 
Daarnaast is hij actief geweest in het onderwijs door onderdeel uit te maken 
van blokplanningsgroepen en het studenten overleg skillslab. Zijn artsenbul 
haalde hij in 2002, in datzelfde jaar startte hij met het promotieonderzoek dat 
geresulteerd heeft in dit proefschrift. Vanaf 1 oktober 2006 is hij in opleiding tot 
internist (opleider: Prof. dr. C.D.A. Stehouwer). 
Jeroen is getrouwd met Kirsten en heeft twee kinderen: Julian (2004) en Aimée 
(2007). 
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Scientific output 
Original contributions 
J. Nijhuis, F.M.H. van Dielen, J.W.M. Greve, W.A. Buurman. Leptin in morbid 
obese patients, no role for treatment of morbid obesity but important in the post 
operative immune response, Obesity Surgery, 2004;14:476-483. 
  
J. Nijhuis, F.M.H. van Dielen, J.W.M. Greve, W.A. Buurman. Ghrelin, leptin 
and insulin levels after restrictive surgery, a 2 year follow-up study. Obesity 
Surgery, 2004;14:783-787. 
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